drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3 values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00618 | DB00819 | 1,572 | 471 | [
"DDInter498",
"DDInter15"
] | Demeclocycline | Acetazolamide | A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time. | One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337) | Minor | 0 | [
[
[
1572,
23,
471
]
],
[
[
1572,
23,
997
],
[
997,
40,
471
]
],
[
[
1572,
1,
1545
],
[
1545,
23,
471
]
],
[
[
1572,
40,
964
],
[
964,
... | [
[
[
"Demeclocycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acetazolamide"
]
],
[
[
"Demeclocycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methazolamide"
]... | Demeclocycline may cause a minor interaction that can limit clinical effects when taken with Methazolamide and Methazolamide (Compound) resembles Acetazolamide (Compound)
Demeclocycline (Compound) resembles Oxytetracycline (Compound) and Oxytetracycline may cause a minor interaction that can limit clinical effects when taken with Acetazolamide
Demeclocycline (Compound) resembles Doxycycline (Compound) and Doxycycline may cause a minor interaction that can limit clinical effects when taken with Acetazolamide
Demeclocycline (Compound) resembles Minocycline (Compound) and Minocycline may cause a minor interaction that can limit clinical effects when taken with Acetazolamide
Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Acetazolamide
Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Acetazolamide
Demeclocycline may lead to a major life threatening interaction when taken with Aminolevulinic acid and Aminolevulinic acid may lead to a major life threatening interaction when taken with Acetazolamide
Demeclocycline may cause a minor interaction that can limit clinical effects when taken with Methazolamide and Methazolamide (Compound) treats glaucoma (Disease) and glaucoma (Disease) is treated by Acetazolamide (Compound)
Demeclocycline (Compound) resembles Oxytetracycline (Compound) and Oxytetracycline may cause a minor interaction that can limit clinical effects when taken with Methazolamide and Methazolamide (Compound) resembles Acetazolamide (Compound) |
DB00073 | DB10315 | 1,394 | 1,137 | [
"DDInter1608",
"DDInter1127"
] | Rituximab | Measles virus vaccine live attenuated | Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences, [FDA label]. It was originally approved by the U.S. FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL), however, has now been approved for a variety of conditions [FDA label]. On November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab). | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Major | 2 | [
[
[
1394,
25,
1137
]
],
[
[
1394,
64,
581
],
[
581,
25,
1137
]
],
[
[
1394,
63,
1184
],
[
1184,
25,
1137
]
],
[
[
1394,
25,
1064
],
[
1064... | [
[
[
"Rituximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Rituximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"... | Rituximab may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Rituximab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Rituximab may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Rituximab may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Measles virus vaccine live attenuated
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Measles virus vaccine live attenuated
Rituximab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Measles virus vaccine live attenuated |
DB00346 | DB09020 | 472 | 28 | [
"DDInter44",
"DDInter212"
] | Alfuzosin | Bisacodyl | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70. Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck. It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies. | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 25 September 1956 but has been used as a laxative since 1952. | Moderate | 1 | [
[
[
472,
24,
28
]
],
[
[
472,
21,
28666
],
[
28666,
60,
28
]
],
[
[
472,
24,
823
],
[
823,
63,
28
]
],
[
[
472,
25,
982
],
[
982,
63... | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Alfuzosin",
"{u} (Compound) causes {v} (Side Effect)",
"Nervous system disorder"
],
[
"Nervous system disorder",
"... | Alfuzosin (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Bisacodyl (Compound)
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Alfuzosin may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Alfuzosin may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Alfuzosin may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Alfuzosin (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Dronedarone (Compound) and Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Alfuzosin (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Carbinoxamine (Compound) and Carbinoxamine (Compound) resembles Bisacodyl (Compound) |
DB08901 | DB15091 | 1,468 | 676 | [
"DDInter1492",
"DDInter1901"
] | Ponatinib | Upadacitinib | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis. To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed. The FDA approved upadacitinib in August 2019 and it is used for the treatment of active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis. In December 2019, it was additionally approved by the European Commission and Health Canada.[L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration. | Major | 2 | [
[
[
1468,
25,
676
]
],
[
[
1468,
63,
1430
],
[
1430,
24,
676
]
],
[
[
1468,
24,
748
],
[
748,
24,
676
]
],
[
[
1468,
25,
283
],
[
283,
... | [
[
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleuc... | Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine and Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Ponatinib may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan and Somapacitan may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Ponatinib may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Upadacitinib
Ponatinib may lead to a major life threatening interaction when taken with Zanubrutinib and Zanubrutinib may lead to a major life threatening interaction when taken with Upadacitinib
Ponatinib may lead to a major life threatening interaction when taken with Posaconazole and Posaconazole may lead to a major life threatening interaction when taken with Upadacitinib
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may lead to a major life threatening interaction when taken with Upadacitinib |
DB06603 | DB08871 | 39 | 36 | [
"DDInter1387",
"DDInter666"
] | Panobinostat | Eribulin | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors . | Major | 2 | [
[
[
39,
25,
36
]
],
[
[
39,
63,
122
],
[
122,
23,
36
]
],
[
[
39,
62,
1247
],
[
1247,
23,
36
]
],
[
[
39,
64,
519
],
[
519,
24,
... | [
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eribulin"
]
],
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verapamil"
],
[
"Verapamil... | Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Verapamil and Verapamil may cause a minor interaction that can limit clinical effects when taken with Eribulin
Panobinostat may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Eribulin
Panobinostat may lead to a major life threatening interaction when taken with Paliperidone and Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated) and Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Panobinostat may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Panobinostat may lead to a major life threatening interaction when taken with Oliceridine and Oliceridine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Panobinostat may lead to a major life threatening interaction when taken with Degarelix and Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Eribulin |
DB00375 | DB00595 | 1,037 | 1,545 | [
"DDInter433",
"DDInter1374"
] | Colestipol | Oxytetracycline | Bile acid sequestrants like colestipol have been in use since the 1970s.[FDA Label, F4555, F4567, L6262] And even though such an agent may very well be useful in reducing elevated cholesterol levels and decreasing the risk for atherosclerotic vascular disease due to hypercholesterolemia, colestipol is still generally only employed as an adjunct therapy and the relatively physical nature of its pharmacological activity sometimes limits its usefulness.[FDA Label, F4555, F4567, L6262] In particular, as colestipol's general mechanism of action ultimately results in the decreased absorption and enhanced secretion of bile acids and lipids in the feces, patients who take complicated medication regimens, experience constipation or biliary obstruction, etc. may not be good candidates for using the agent owing to its physical effects on the gut.[FDA Label, F4555, F4567, L | A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions. | Minor | 0 | [
[
[
1037,
23,
1545
]
],
[
[
1037,
62,
964
],
[
964,
1,
1545
]
],
[
[
1037,
23,
1620
],
[
1620,
1,
1545
]
],
[
[
1037,
25,
1096
],
[
1096,
... | [
[
[
"Colestipol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Oxytetracycline"
]
],
[
[
"Colestipol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doxycycline"
],
[
... | Colestipol may cause a minor interaction that can limit clinical effects when taken with Doxycycline and Doxycycline (Compound) resembles Oxytetracycline (Compound)
Colestipol may cause a minor interaction that can limit clinical effects when taken with Tetracycline and Tetracycline (Compound) resembles Oxytetracycline (Compound)
Colestipol may lead to a major life threatening interaction when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Oxytetracycline
Colestipol may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Oxytetracycline
Colestipol may cause a minor interaction that can limit clinical effects when taken with Doxycycline and Doxycycline (Compound) resembles Tigecycline (Compound) and Tigecycline (Compound) resembles Oxytetracycline (Compound)
Colestipol may cause a minor interaction that can limit clinical effects when taken with Tetracycline and Tetracycline (Compound) resembles Doxycycline (Compound) and Doxycycline (Compound) resembles Oxytetracycline (Compound)
Colestipol may cause a minor interaction that can limit clinical effects when taken with Minocycline and Minocycline (Compound) resembles Doxycycline (Compound) and Doxycycline (Compound) resembles Oxytetracycline (Compound)
Colestipol may lead to a major life threatening interaction when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline (Compound) resembles Oxytetracycline (Compound)
Colestipol (Compound) causes Digestion impaired (Side Effect) and Digestion impaired (Side Effect) is caused by Dicloxacillin (Compound) and Dicloxacillin may cause a moderate interaction that could exacerbate diseases when taken with Oxytetracycline |
DB00284 | DB00603 | 1,647 | 303 | [
"DDInter11",
"DDInter1137"
] | Acarbose | Medroxyprogesterone acetate | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are responsible for the metabolism of complex starches and oligo-, tri-, and disaccharides into absorbable simple sugars.[L31633,A37868] By inhibiting the activity of these enzymes, acarbose limits the absorption of dietary carbohydrates and the subsequent postprandial increase in blood glucose and insulin levels. Acarbose is therefore used in conjunction with diet, exercise, and other pharmacotherapies for the management of blood sugar levels in patients with type 2 diabetes.[L31628,L31633] Acarbose is one of only two approved alpha-glucosidase inhibitors (the other being | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy, manage pain in endometriosis, prevent pregnancy, and is also used in palliative care for endometrial and renal carcinoma.[L8657,L8660,L8663,L8666,L8669] Medroxyprogesterone acetate was granted FDA approval on 18 June 1959. | Moderate | 1 | [
[
[
1647,
24,
303
]
],
[
[
1647,
24,
167
],
[
167,
1,
303
]
],
[
[
1647,
21,
28809
],
[
28809,
60,
303
]
],
[
[
1647,
63,
215
],
[
215,
... | [
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Medroxyprogesterone acetate"
]
],
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone... | Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Medroxyprogesterone acetate (Compound)
Acarbose (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Medroxyprogesterone acetate (Compound)
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Indinavir and Indinavir may cause a minor interaction that can limit clinical effects when taken with Medroxyprogesterone acetate
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate
Acarbose may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate
Acarbose may cause a minor interaction that can limit clinical effects when taken with Albiglutide and Albiglutide may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate
Acarbose may cause a minor interaction that can limit clinical effects when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate |
DB00582 | DB08868 | 1,622 | 1,011 | [
"DDInter1946",
"DDInter737"
] | Voriconazole | Fingolimod | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increased affinity of voriconazole for 14-alpha sterol demethylase makes it useful against some [fluconazole]-resistant organisms. Voriconazole was approved by the FDA under the trade name Vfend on May 24, 2002. | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.[L12654,L12657] | Major | 2 | [
[
[
1622,
25,
1011
]
],
[
[
1622,
6,
8374
],
[
8374,
45,
1011
]
],
[
[
1622,
21,
28892
],
[
28892,
60,
1011
]
],
[
[
1622,
25,
578
],
[
57... | [
[
[
"Voriconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Voriconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Fin... | Voriconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fingolimod (Compound)
Voriconazole (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by Fingolimod (Compound)
Voriconazole may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Fingolimod
Voriconazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Fingolimod
Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Voriconazole may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Voriconazole may lead to a major life threatening interaction when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod |
DB11691 | DB11952 | 1,499 | 800 | [
"DDInter1258",
"DDInter612"
] | Naldemedine | Duvelisib | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation. | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed that this agent is a potent inhibitor of both forms. Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018. | Moderate | 1 | [
[
[
1499,
24,
800
]
],
[
[
1499,
24,
1476
],
[
1476,
63,
800
]
],
[
[
1499,
63,
267
],
[
267,
24,
800
]
],
[
[
1499,
24,
351
],
[
351,
... | [
[
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
... | Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Duvelisib
Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may lead to a major life threatening interaction when taken with Duvelisib
Naldemedine may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Duvelisib
Naldemedine may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Duvelisib
Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Duvelisib
Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib |
DB00845 | DB09020 | 1,490 | 28 | [
"DDInter406",
"DDInter212"
] | Clofazimine | Bisacodyl | Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin and bodily fluids. Although it carries _in vitro_ activity against other mycobacterium, such as _Mycobacterium tuberculosis_, it is generally considered an ineffective treatment in comparison to classic tuberculosis treatments such as [rifampicin] and [isoniazid]. | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 25 September 1956 but has been used as a laxative since 1952. | Moderate | 1 | [
[
[
1490,
24,
28
]
],
[
[
1490,
7,
6717
],
[
6717,
46,
28
]
],
[
[
1490,
21,
28809
],
[
28809,
60,
28
]
],
[
[
1490,
24,
823
],
[
823,
... | [
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Clofazimine",
"{u} (Compound) upregulates {v} (Gene)",
"HERPUD1"
],
[
"HERPUD1",
"{u} (Gene) is upregulated by {... | Clofazimine (Compound) upregulates HERPUD1 (Gene) and HERPUD1 (Gene) is upregulated by Bisacodyl (Compound)
Clofazimine (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Bisacodyl (Compound)
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Clofazimine may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Clofazimine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Clofazimine may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Astemizole and Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Clofazimine (Compound) upregulates HERPUD1 (Gene) and HERPUD1 (Gene) is regulated by CNOT4 (Gene) and CNOT4 (Gene) is upregulated by Bisacodyl (Compound) |
DB00366 | DB01168 | 1,594 | 1,053 | [
"DDInter600",
"DDInter1526"
] | Doxylamine | Procarbazine | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Major | 2 | [
[
[
1594,
25,
1053
]
],
[
[
1594,
21,
29119
],
[
29119,
60,
1053
]
],
[
[
1594,
24,
9
],
[
9,
63,
1053
]
],
[
[
1594,
24,
100
],
[
100,
... | [
[
[
"Doxylamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Doxylamine",
"{u} (Compound) causes {v} (Side Effect)",
"Haemolytic anaemia"
],
[
"Haemolytic anaemia",
"{u} (Side Effect) is... | Doxylamine (Compound) causes Haemolytic anaemia (Side Effect) and Haemolytic anaemia (Side Effect) is caused by Procarbazine (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine and Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Doxylamine (Compound) resembles Chlorpheniramine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Doxylamine (Compound) resembles Clemastine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Tapentadol and Tapentadol may lead to a major life threatening interaction when taken with Procarbazine
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine may lead to a major life threatening interaction when taken with Procarbazine
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mirtazapine and Mirtazapine may lead to a major life threatening interaction when taken with Procarbazine |
DB09085 | DB15373 | 587 | 1,256 | [
"DDInter1779",
"DDInter1807"
] | Tetracaine | Tilmanocept | Tetracaine is an ester local anaesthetic currently available in combination with lidocaine as a cream and patch. | Tilmanocept is under investigation in clinical trial NCT03241446 (Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)). | Moderate | 1 | [
[
[
587,
24,
1256
]
],
[
[
587,
23,
771
],
[
771,
62,
608
],
[
608,
24,
1256
]
],
[
[
587,
63,
1119
],
[
1119,
63,
608
],
[
608,
24,
... | [
[
[
"Tetracaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tilmanocept"
]
],
[
[
"Tetracaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
[
... | Tetracaine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Tilmanocept
Tetracaine may cause a moderate interaction that could exacerbate diseases when taken with Chlordiazepoxide and Chlordiazepoxide may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Tilmanocept
Tetracaine may cause a moderate interaction that could exacerbate diseases when taken with Lorazepam and Lorazepam may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Tilmanocept
Tetracaine may lead to a major life threatening interaction when taken with Nitrous acid and Nitrous acid may lead to a major life threatening interaction when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Tilmanocept |
DB01236 | DB06616 | 679 | 594 | [
"DDInter1664",
"DDInter224"
] | Sevoflurane | Bosutinib | Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 1996. Sevoflurane is three times more potent than [desflurane], but has lower potency compared to [halothane] and [isoflurane]. Unlike other volatile anesthetics, sevoflurane has a pleasant odor and does not irritate the airway. The hemodynamic and respiratory depressive effects of sevoflurane are well tolerated, and most patients receiving this anesthetic agent present little toxicity. Therefore, it can be used for inhalational induction in adults and children for a wide variety of anesthetic procedures. | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving remission. Second-generation BCR-ABL inhibitors like bosutinib inhibit most resistance-conferring BCR-ABL mutations except V299L and T315, thus providing more therapeutic options for patients.[A6901,A17961] Bosutinib was first approved by the FDA in 2012 for the treatment of adult chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy. On September 26, 2023, bosutinib was also approved by the FDA for the treatment of pediatric CML that is newly diagnosed or resistant/intolerant to prior therapy. This approval was based on favorable results obtained from the open-label, randomized, multicenter trial BFORE that showed a significant improvement in major molecular response, defined as a ≤0.1% BCR ABL ratio on an international scale, with bosutinib treatment. | Moderate | 1 | [
[
[
679,
24,
594
]
],
[
[
679,
6,
8374
],
[
8374,
45,
594
]
],
[
[
679,
21,
29231
],
[
29231,
60,
594
]
],
[
[
679,
62,
112
],
[
112,
... | [
[
[
"Sevoflurane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Sevoflurane",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Sevoflurane (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Sevoflurane (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Bosutinib (Compound)
Sevoflurane may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bosutinib
Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken with Degarelix and Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Sevoflurane (Compound) resembles Perflutren (Compound) and Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Sevoflurane may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Sevoflurane may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Bosutinib |
DB00215 | DB01362 | 1,230 | 497 | [
"DDInter388",
"DDInter960"
] | Citalopram | Iohexol | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] Citalopram enhances serotonergic transmission through the inhibition of serotonin reuptake, and among all the SSRIs, citalopram appears to be the most selective toward serotonin reuptake inhibition.[A261316,A14720] Specifically, it has a very minimal effect on dopamine and norepinephrine transportation and virtually no affinity for muscarinic, histaminergic, or GABAergic receptors. Citalopram was approved by the FDA in 1998 for the treatment of depression in adults 18 years or older. | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
1230,
25,
497
]
],
[
[
1230,
21,
28681
],
[
28681,
60,
497
]
],
[
[
1230,
24,
1574
],
[
1574,
63,
497
]
],
[
[
1230,
24,
999
],
[
999,... | [
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Citalopram",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused b... | Citalopram (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Iohexol (Compound)
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Urea and Urea may cause a moderate interaction that could exacerbate diseases when taken with Iohexol
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may lead to a major life threatening interaction when taken with Iohexol
Citalopram (Compound) resembles Escitalopram (Compound) and Es
Citalopram may lead to a major life threatening interaction when taken with Doxepin and Doxepin may lead to a major life threatening interaction when taken with Iohexol
Citalopram may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Iohexol
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may lead to a major life threatening interaction when taken with Iohexol
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Iobenguane may lead to a major life threatening interaction when taken with Iohexol
Citalopram may lead to a major life threatening interaction when taken with Phentermine and Phentermine may lead to a major life threatening interaction when taken with Iohexol |
DB00533 | DB00945 | 1,416 | 1,479 | [
"DDInter1613",
"DDInter20"
] | Rofecoxib | Acetylsalicylic acid | Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids. Rofecoxib has a half-life of 17 hours and its mean oral bioavailability at therapeutically recommended doses of 125, 25, and 50 mg is approximately 93%. The proteins that rofecoxib target include elastin and prostaglandin G/H synthase 2 | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) [FDA label]. Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a _non-selective cyclooxygenase (COX) inhibitor_ [A32682, A177268] and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others . Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants [FDA label]. | Moderate | 1 | [
[
[
1416,
24,
1479
]
],
[
[
1416,
63,
1314
],
[
1314,
23,
1479
]
],
[
[
1416,
24,
714
],
[
714,
63,
1479
]
],
[
[
1416,
63,
1271
],
[
1271... | [
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desmopressin"
]... | Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Desmopressin and Desmopressin may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Alteplase and Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Tirofiban and Tirofiban may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab and Caplacizumab may lead to a major life threatening interaction when taken with Acetylsalicylic acid
Rofecoxib may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Acetylsalicylic acid
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may lead to a major life threatening interaction when taken with Acetylsalicylic acid
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Desmopressin and Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid |
DB00604 | DB09054 | 1,425 | 384 | [
"DDInter385",
"DDInter905"
] | Cisapride | Idelalisib | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability. | Major | 2 | [
[
[
1425,
25,
384
]
],
[
[
1425,
25,
318
],
[
318,
23,
384
]
],
[
[
1425,
64,
1230
],
[
1230,
23,
384
]
],
[
[
1425,
24,
307
],
[
307,
... | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
],
[
"Escitalopram",
"{u}... | Cisapride may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Cisapride may lead to a major life threatening interaction when taken with Citalopram and Citalopram may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Cisapride may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib and Erdafitinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Cisapride may lead to a major life threatening interaction when taken with Azithromycin and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Nevirapine and Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Cisapride may lead to a major life threatening interaction when taken with Lenvatinib and Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib |
DB00001 | DB06754 | 1,578 | 707 | [
"DDInter1037",
"DDInter471"
] | Lepirudin | Danaparoid | Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches. Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence of sulfate on the tyrosine residue at position 63 and the substitution of leucine for isoleucine at position 1 (N-terminal end). Lepirudin is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT), an immune reaction associated with a high risk of thromboembolic complications.[A3, L41539] HIT is caused by the expression of immunoglobulin G (IgG) antibodies that bind to the complex formed by heparin and | Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity that works by inhibiting activated factor X (Factor Xa) and activated factor II (Factor IIa). It is chemically distinct from heparin by containing different protein binding properties, thus has lower cross-reactivity in heparin-intolerant patients. Danaproid is used in the treatment of heparin-induced thrombocytopenia (HIT) as an off-label indication and prevention of post-operative deep venous thrombosis (DVT). While it was initially approved by the FDA as Orgaran™, danaparoid was withdrawn by Organon International on August 14, 2002, due to a shortage in drug substance by the manufacturer. The use of Orgaran™ was discontinued in the United States however it is available in several other countries including European countries and Japan. Danaparoid sodium is the common salt form in therapeutic preparations and is typically administered subcutaneously. | Major | 2 | [
[
[
1578,
25,
707
]
],
[
[
1578,
23,
944
],
[
944,
62,
707
]
],
[
[
1578,
24,
298
],
[
298,
63,
707
]
],
[
[
1578,
24,
901
],
[
901,
... | [
[
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
]
],
[
[
"Lepirudin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
... | Lepirudin may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Danaparoid
Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Protein C and Protein C may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Lepirudin may lead to a major life threatening interaction when taken with Desirudin and Desirudin may lead to a major life threatening interaction when taken with Danaparoid
Lepirudin may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan and Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Danaparoid
Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen may lead to a major life threatening interaction when taken with Danaparoid
Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may lead to a major life threatening interaction when taken with Danaparoid
Lepirudin may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Ibritumomab tiuxetan and Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Danaparoid
Lepirudin may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Desirudin and Desirudin may lead to a major life threatening interaction when taken with Danaparoid |
DB00771 | DB01267 | 262 | 519 | [
"DDInter397",
"DDInter1381"
] | Clidinium | Paliperidone | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome. | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. It is available as an extended-release tablet, a once-monthly intramuscular injection, an every-three-month intramuscular injection, and a twice-yearly gluteal injection.[L16168,L37744,L4137,L37749] | Moderate | 1 | [
[
[
262,
24,
519
]
],
[
[
262,
63,
1664
],
[
1664,
1,
519
]
],
[
[
262,
24,
924
],
[
924,
1,
519
]
],
[
[
262,
24,
1192
],
[
1192,
2... | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
... | Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Paliperidone (Compound)
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Iloperidone and Iloperidone (Compound) resembles Paliperidone (Compound)
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine and Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide and Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
Clidinium (Compound) resembles Trospium (Compound) and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may lead to a major life threatening interaction when taken with Paliperidone
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Paliperidone
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound) and Iloperidone (Compound) resembles Paliperidone (Compound) |
DB00865 | DB09268 | 939 | 1,662 | [
"DDInter187",
"DDInter1464"
] | Benzphetamine | Picosulfuric acid | A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222) | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years. | Moderate | 1 | [
[
[
939,
24,
1662
]
],
[
[
939,
40,
1164
],
[
1164,
24,
1662
]
],
[
[
939,
64,
73
],
[
73,
24,
1662
]
],
[
[
939,
1,
1405
],
[
1405,
... | [
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Benzphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Trimipramine"
],
[
"Trimipramine",
"{u} ma... | Benzphetamine (Compound) resembles Trimipramine (Compound) and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Benzphetamine may lead to a major life threatening interaction when taken with Phentermine and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Benzphetamine (Compound) resembles Cyclobenzaprine (Compound) and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Benzphetamine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Benzphetamine (Compound) resembles Bepridil (Compound) and Bepridil may lead to a major life threatening interaction when taken with Picosulfuric acid
Benzphetamine (Compound) resembles Levacetylmethadol (Compound) and Levacetylmethadol may lead to a major life threatening interaction when taken with Picosulfuric acid
Benzphetamine (Compound) resembles Trimipramine (Compound) and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid |
DB00009 | DB04865 | 1,271 | 4 | [
"DDInter56",
"DDInter1335"
] | Alteplase | Omacetaxine mepesuccinate | Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin.[A252330,L43125] Alteplase is a purified glycoprotein of 527 amino acids expressed in Chinese hamster ovary (CHO) cells.[A252345,L43125] It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI). The use of alteplase to manage AMI has decreased thanks to the availability of safer treatments such as angioplasty and stenting. However, its use for the treatment of acute ischem | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was marketed under the brand name Synribo and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML. | Major | 2 | [
[
[
1271,
25,
4
]
],
[
[
1271,
24,
738
],
[
738,
63,
4
]
],
[
[
1271,
25,
39
],
[
39,
63,
4
]
],
[
[
1271,
25,
1213
],
[
1213,
24,
... | [
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
... | Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Alteplase may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Alteplase may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
Alteplase may lead to a major life threatening interaction when taken with Avapritinib and Avapritinib may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
Alteplase may lead to a major life threatening interaction when taken with Anisindione and Anisindione may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
Alteplase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Rituximab and Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate |
DB00563 | DB09122 | 663 | 1,613 | [
"DDInter1174",
"DDInter1409"
] | Methotrexate | Peginterferon beta-1a | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953. | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792] Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021. Currently, it is the only approved pegylated interferon for the management of MS with an proven ability to reduce relapses and delay the progression of disability resulting from MS. | Moderate | 1 | [
[
[
663,
24,
1613
]
],
[
[
663,
24,
671
],
[
671,
24,
1613
]
],
[
[
663,
63,
152
],
[
152,
24,
1613
]
],
[
[
663,
24,
975
],
[
975,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Bosentan and Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin and Lurbinectedin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Methotrexate may lead to a major life threatening interaction when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Methotrexate may lead to a major life threatening interaction when taken with Indomethacin and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Methotrexate may cause a minor interaction that can limit clinical effects when taken with Mercaptopurine and Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Methotrexate may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Peginterferon beta-1a
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may lead to a major life threatening interaction when taken with Peginterferon beta-1a
Methotrexate may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Peginterferon beta-1a |
DB00950 | DB12130 | 1,413 | 1,017 | [
"DDInter732",
"DDInter1094"
] | Fexofenadine | Lorlatinib | Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms. It is selective for the H<sub>1</sub> receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier - this is in contrast to previous first-generation antihistamines, such as [diphenhydramine], which readily bind to off-targets that contribute to side effects such as sedation. Fexofenadine is the major active metabolite of [terfenadine] and is administered as a racemic mixture in which both enantiomers display approximately equivalent antihistamine activity. | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. | Moderate | 1 | [
[
[
1413,
24,
1017
]
],
[
[
1413,
24,
1612
],
[
1612,
23,
1017
]
],
[
[
1413,
24,
1491
],
[
1491,
24,
1017
]
],
[
[
1413,
24,
971
],
[
971... | [
[
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
... | Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Fexofenadine (Compound) resembles Darifenacin (Compound) and Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Fexofenadine may cause a minor interaction that can limit clinical effects when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Fexofenadine (Compound) resembles Pimozide (Compound) and Pimozide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Fexofenadine may cause a minor interaction that can limit clinical effects when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Fexofenadine (Compound) resembles Lomitapide (Compound) and Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide and Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib |
DB00526 | DB13139 | 1,555 | 1,032 | [
"DDInter1355",
"DDInter1063"
] | Oxaliplatin | Levosalbutamol | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The | Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective disposition of salbutamol and the possibility that (S)-salbutamol has adverse effects have led to the development of an enantiomerically pure (R)-salbutamol formulation known as levosalbutamol (levalbuterol). | Moderate | 1 | [
[
[
1555,
24,
1032
]
],
[
[
1555,
25,
1618
],
[
1618,
24,
1032
]
],
[
[
1555,
24,
124
],
[
124,
24,
1032
]
],
[
[
1555,
25,
982
],
[
982,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Ca... | Oxaliplatin may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Oxaliplatin may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Oxaliplatin may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Oxaliplatin may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Levosalbutamol
Oxaliplatin may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol
Oxaliplatin may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol |
DB11730 | DB14444 | 351 | 151 | [
"DDInter1588",
"DDInter924"
] | Ribociclib | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali. | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to. There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability. | Moderate | 1 | [
[
[
351,
24,
151
]
],
[
[
351,
63,
66
],
[
66,
24,
151
]
],
[
[
351,
25,
1619
],
[
1619,
24,
151
]
],
[
[
351,
64,
375
],
[
375,
24,... | [
[
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Ribociclib",
"{u} may cause a moderate interaction that could e... | Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Ribociclib may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Ribociclib may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib and Talazoparib may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Ribociclib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Ribociclib may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Ribociclib may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) |
DB00055 | DB12500 | 834 | 283 | [
"DDInter605",
"DDInter714"
] | Drotrecogin alfa | Fedratinib | Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving outcomes in patients with sepsis. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
834,
25,
283
]
],
[
[
834,
25,
885
],
[
885,
24,
283
]
],
[
[
834,
24,
529
],
[
529,
24,
283
]
],
[
[
834,
25,
1564
],
[
1564,
2... | [
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epoprostenol"
],
[
"Epoprosteno... | Drotrecogin alfa may lead to a major life threatening interaction when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Drotrecogin alfa may lead to a major life threatening interaction when taken with Defibrotide and Defibrotide may lead to a major life threatening interaction when taken with Fedratinib
Drotrecogin alfa may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may lead to a major life threatening interaction when taken with Fedratinib
Drotrecogin alfa may lead to a major life threatening interaction when taken with Zanubrutinib and Zanubrutinib may lead to a major life threatening interaction when taken with Fedratinib
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram may lead to a major life threatening interaction when taken with Fedratinib
Drotrecogin alfa may lead to a major life threatening interaction when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Verapamil and Verapamil may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib |
DB00372 | DB09488 | 999 | 103 | [
"DDInter1793",
"DDInter23"
] | Thiethylperazine | Acrivastine | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema, bronchoconstriction, and tachycardia. Acrivastine is currently available in combination with pseudoephedrine as the FDA-approved product Semprex-D. | Moderate | 1 | [
[
[
999,
24,
103
]
],
[
[
999,
24,
1405
],
[
1405,
24,
103
]
],
[
[
999,
63,
357
],
[
357,
24,
103
]
],
[
[
999,
24,
418
],
[
418,
6... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprin... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Benzatropine and Benzatropine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone and Brexanolone may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Thiethylperazine may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Thiethylperazine may lead to a major life threatening interaction when taken with Zonisamide and Zonisamide may lead to a major life threatening interaction when taken with Acrivastine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may lead to a major life threatening interaction when taken with Cyclobenzaprine and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Benzatropine and Benzatropine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine |
DB01168 | DB09571 | 1,053 | 1,308 | [
"DDInter1526",
"DDInter1047"
] | Procarbazine | Levmetamfetamine (nasal) | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Levmetamfetamine is a member of amphetamines. | Moderate | 1 | [
[
[
1053,
24,
1308
]
],
[
[
1053,
63,
1052
],
[
1052,
24,
1629
],
[
1629,
24,
1308
]
],
[
[
1053,
24,
697
],
[
697,
24,
1629
],
[
1629,
... | [
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levmetamfetamine"
]
],
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
],... | Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Levmetamfetamine
Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue and Methylene blue may cause a moderate interaction that could exacerbate diseases when taken with Levmetamfetamine
Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue and Methylene blue may cause a moderate interaction that could exacerbate diseases when taken with Levmetamfetamine
Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol and Levosalbutamol may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue and Methylene blue may cause a moderate interaction that could exacerbate diseases when taken with Levmetamfetamine
Procarbazine may lead to a major life threatening interaction when taken with Phentermine and Phentermine may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may cause a moderate interaction that could exacerbate diseases when taken with Levmetamfetamine
Procarbazine may lead to a major life threatening interaction when taken with Dezocine and Dezocine may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may cause a moderate interaction that could exacerbate diseases when taken with Levmetamfetamine
Procarbazine may lead to a major life threatening interaction when taken with Valbenazine and Valbenazine may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may cause a moderate interaction that could exacerbate diseases when taken with Levmetamfetamine
Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline and Procarbazine may lead to a major life threatening interaction when taken with Tetryzoline and Tetryzoline may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue and Tetryzoline may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may cause a moderate interaction that could exacerbate diseases when taken with Levmetamfetamine |
DB00598 | DB09340 | 1,523 | 1,013 | [
"DDInter1013",
"DDInter1895"
] | Labetalol | Tyropanoic acid | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Tyropanoic acid is a radiocontrast agent used in cholecystography, the X-ray diagnosis of gallstones under the trade names include Bilopaque, Lumopaque, Tyropaque, and Bilopac. The molecule contains three heavy iodine atoms which obstruct X-rays in the same way as the calcium in bones, which results in a visible image . | Moderate | 1 | [
[
[
1523,
24,
1013
]
],
[
[
1523,
24,
777
],
[
777,
24,
1013
]
],
[
[
1523,
63,
1648
],
[
1648,
24,
1013
]
],
[
[
1523,
24,
777
],
[
777,
... | [
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tyropanoic acid"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopromide"
],
[
... | Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Iopromide and Iopromide may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Iopromide and Iopromide may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Gadopentetic acid and Gadopentetic acid may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine and Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine and Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a minor interaction that can limit clinical effects when taken with Cholestyramine and Cholestyramine may cause a minor interaction that can limit clinical effects when taken with Tyropanoic acid
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a minor interaction that can limit clinical effects when taken with Cholestyramine and Cholestyramine may cause a minor interaction that can limit clinical effects when taken with Tyropanoic acid
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid and Iopodic acid may cause a minor interaction that can limit clinical effects when taken with Cholestyramine and Cholestyramine may cause a minor interaction that can limit clinical effects when taken with Tyropanoic acid
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Iopromide and Iopromide may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid |
DB00213 | DB00529 | 837 | 789 | [
"DDInter1388",
"DDInter779"
] | Pantoprazole | Foscarnet | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be found in quadruple regimens for the treatment of _H. pylori_ infections along with other antibiotics including [amoxicillin], [clarithromycin], and [metronidazole], for example. Its efficacy is considered similar to other medications within the PPI class including [omeprazole], [esomeprazole], [lansoprazole], [dexlansoprazole], and [rabeprazole]. Pantoprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Moderate | 1 | [
[
[
837,
24,
789
]
],
[
[
837,
21,
29785
],
[
29785,
60,
789
]
],
[
[
837,
24,
1297
],
[
1297,
63,
789
]
],
[
[
837,
1,
1215
],
[
1215,
... | [
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Foscarnet"
]
],
[
[
"Pantoprazole",
"{u} (Compound) causes {v} (Side Effect)",
"Abscess"
],
[
"Abscess",
"{u} (Side Effect) is cause... | Pantoprazole (Compound) causes Abscess (Side Effect) and Abscess (Side Effect) is caused by Foscarnet (Compound)
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet
Pantoprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet
Pantoprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet
Pantoprazole may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin may lead to a major life threatening interaction when taken with Foscarnet
Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Vandetanib and Vandetanib may lead to a major life threatening interaction when taken with Foscarnet |
DB00757 | DB01015 | 1,166 | 1,247 | [
"DDInter581",
"DDInter1724"
] | Dolasetron | Sulfamethoxazole | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors. | Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance. In this combination, sulfamethoxazole is useful for the treatment of a variety of bacterial infections, including those of the urinary, respiratory, and gastrointestinal tracts. | Minor | 0 | [
[
[
1166,
23,
1247
]
],
[
[
1166,
6,
6017
],
[
6017,
45,
1247
]
],
[
[
1166,
21,
28804
],
[
28804,
60,
1247
]
],
[
[
1166,
64,
11
],
[
11,... | [
[
[
"Dolasetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
]
],
[
[
"Dolasetron",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compoun... | Dolasetron (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Sulfamethoxazole (Compound)
Dolasetron (Compound) causes Purpura (Side Effect) and Purpura (Side Effect) is caused by Sulfamethoxazole (Compound)
Dolasetron may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Dolasetron may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Dolasetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Dolasetron may lead to a major life threatening interaction when taken with Granisetron and Granisetron may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Dolasetron may lead to a major life threatening interaction when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole |
DB00405 | DB00494 | 128 | 1,533 | [
"DDInter517",
"DDInter646"
] | Dexbrompheniramine | Entacapone | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa concentrations are reached as compared to the administration of levodopa and a decarboxylase inhibitor. | Moderate | 1 | [
[
[
128,
24,
1533
]
],
[
[
128,
63,
1062
],
[
1062,
1,
1533
]
],
[
[
128,
24,
770
],
[
770,
63,
1533
]
],
[
[
128,
63,
701
],
[
701,
... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entacapone"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolcapone"
... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tolcapone and Tolcapone (Compound) resembles Entacapone (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Entacapone
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Entacapone
Dexbrompheniramine (Compound) resembles Doxylamine (Compound) and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Entacapone
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Entacapone
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Entacapone
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tolcapone and Tolcapone (Compound) binds COMT (Gene) and COMT (Gene) is bound by Entacapone (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Tolcapone and Tolcapone (Compound) resembles Entacapone (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Tolcapone and Tolcapone (Compound) resembles Entacapone (Compound) |
DB06273 | DB06317 | 980 | 1,626 | [
"DDInter1824",
"DDInter630"
] | Tocilizumab | Elotuzumab | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflammatory and autoimmune disorders, such as different types of arthritis and cytokine release syndrome. It was later approved by Health Canada on 30 April 2010. After being investigated to treat severely ill patients with COVID-19,[A193278,L12837,L12843] tocilizumab was approved by the European Commission in December 2021 to treat COVID-19 in adults receiving systemic corticosteroids and supplemental oxygen or mechanical ventilation. Subsequently, it was granted approval by Health Canada and the FDA in October and December 2022, respectively. Tociliz | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks. Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration. Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb. | Moderate | 1 | [
[
[
980,
24,
1626
]
],
[
[
980,
63,
973
],
[
973,
24,
1626
]
],
[
[
980,
24,
200
],
[
200,
63,
1626
]
],
[
[
980,
64,
1531
],
[
1531,
... | [
[
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
... | Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Tocilizumab may lead to a major life threatening interaction when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Tocilizumab may lead to a major life threatening interaction when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Tocilizumab may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Elotuzumab
Tocilizumab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Elotuzumab
Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab |
DB00771 | DB01203 | 262 | 699 | [
"DDInter397",
"DDInter1255"
] | Clidinium | Nadolol | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome. | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adverse effects. Nadolol was granted FDA approval on 10 December 1979. | Moderate | 1 | [
[
[
262,
24,
699
]
],
[
[
262,
24,
729
],
[
729,
1,
699
]
],
[
[
262,
63,
1442
],
[
1442,
24,
699
]
],
[
[
262,
24,
820
],
[
820,
63... | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nadolol"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
],
[
"... | Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol (Compound) resembles Nadolol (Compound)
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine and Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Nadolol
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Nadolol
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Nadolol
Clidinium (Compound) resembles Trospium (Compound) and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Nadolol
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol (Compound) resembles Carteolol (Compound) and Carteolol (Compound) resembles Nadolol (Compound)
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine and Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol (Compound) resembles Nadolol (Compound)
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Pindolol and Pindolol (Compound) resembles Nadolol (Compound)
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol (Compound) resembles Nadolol (Compound) |
DB00620 | DB06335 | 175 | 761 | [
"DDInter1855",
"DDInter1646"
] | Triamcinolone | Saxagliptin | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957. In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval - for the treatment of patients with macular | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
175,
24,
761
]
],
[
[
175,
6,
8374
],
[
8374,
45,
761
]
],
[
[
175,
21,
28966
],
[
28966,
60,
761
]
],
[
[
175,
23,
307
],
[
307,
... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Triamcinolone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Comp... | Triamcinolone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Saxagliptin (Compound)
Triamcinolone (Compound) causes Upper respiratory tract infection (Side Effect) and Upper respiratory tract infection (Side Effect) is caused by Saxagliptin (Compound)
Triamcinolone may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Saxagliptin
Triamcinolone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Saxagliptin
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide and Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Triamcinolone (Compound) resembles Prednisone (Compound) and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Triamcinolone may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin |
DB01144 | DB11827 | 1,326 | 433 | [
"DDInter540",
"DDInter669"
] | Diclofenamide | Ertugliflozin | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
1326,
24,
433
]
],
[
[
1326,
63,
959
],
[
959,
24,
433
]
],
[
[
1326,
24,
885
],
[
885,
24,
433
]
],
[
[
1326,
24,
1019
],
[
1019,
... | [
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
... | Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Diclofenamide (Compound) resembles Hydrochlorothiazide (Compound) and Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Diclofenamide (Compound) resembles Trichlormethiazide (Compound) and Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Ertugliflozin
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Ertugliflozin
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Ertugliflozin
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin |
DB00514 | DB01081 | 506 | 1,688 | [
"DDInter527",
"DDInter571"
] | Dextromethorphan | Diphenoxylate | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | A meperidine congener used as an antidiarrheal, usually in combination with atropine. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity. This medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations. When diphenoxylate is used alone, it is classified as a Schedule II. | Moderate | 1 | [
[
[
506,
24,
1688
]
],
[
[
506,
63,
576
],
[
576,
1,
1688
]
],
[
[
506,
24,
1118
],
[
1118,
1,
1688
]
],
[
[
506,
63,
194
],
[
194,
... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenoxylate"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
... | Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone (Compound) resembles Diphenoxylate (Compound)
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Difenoxin and Difenoxin (Compound) resembles Diphenoxylate (Compound)
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Darifenacin and Darifenacin (Compound) resembles Diphenoxylate (Compound)
Dextromethorphan (Compound) binds OPRM1 (Gene) and OPRM1 (Gene) is bound by Diphenoxylate (Compound)
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Ketamine and Ketamine may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Droperidol and Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Dexmedetomidine and Dexmedetomidine may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate
Dextromethorphan may lead to a major life threatening interaction when taken with Citalopram and Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate
Dextromethorphan may lead to a major life threatening interaction when taken with Desvenlafaxine and Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate |
DB00496 | DB00574 | 194 | 121 | [
"DDInter480",
"DDInter717"
] | Darifenacin | Fenfluramine | Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor selectivity is clinically advantageous in overactive bladder syndrome treatments. | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients typically display delayed development and neurocognitive impairment.[A214694, A214709, A214712, A214715] Fenfluramine is a serotonergic phenethylamine originally used as an appetite suppressant until concerns regarding cardiotoxicity in obese patients lead to its withdrawal from the market in 1997.[A214694, A214718, A11906] Through its ability to modulate neurotransmission, fenfluramine has reemerged as an effective therapy against pharmacoresistant seizures, such as those involved in Dravet syndrome.[A214688, A214691, A214700] Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal; it was granted a new FDA approval on June 25, 2020, for treatment of patients with Dravet syndrome and Lennox-Gastaut syndrome through the restricted FINTEPLA REMS program. It is currently sold under the name FINTEPLA® by Zogenix INC. | Moderate | 1 | [
[
[
194,
24,
121
]
],
[
[
194,
25,
1670
],
[
1670,
63,
121
]
],
[
[
194,
24,
868
],
[
868,
63,
121
]
],
[
[
194,
63,
1018
],
[
1018,
... | [
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
]
],
[
[
"Darifenacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
],
[
"Eliglu... | Darifenacin may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Darifenacin (Compound) resembles Methadone (Compound) and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may lead to a major life threatening interaction when taken with Fenfluramine
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may lead to a major life threatening interaction when taken with Fenfluramine
Darifenacin may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may lead to a major life threatening interaction when taken with Fenfluramine
Darifenacin (Compound) resembles Fentanyl (Compound) and Fentanyl may lead to a major life threatening interaction when taken with Fenfluramine
Darifenacin may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause a minor interaction that can limit clinical effects when taken with Tolterodine and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Fenfluramine |
DB00981 | DB01591 | 1,528 | 667 | [
"DDInter1463",
"DDInter1696"
] | Physostigmine (ophthalmic) | Solifenacin | Physostigmine is a carbamate ester and an indole alkaloid. It has a role as a miotic, an EC 3.1.1.8 (cholinesterase) inhibitor and an antidote to curare poisoning. | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Moderate | 1 | [
[
[
1528,
24,
667
]
],
[
[
1528,
21,
28722
],
[
28722,
60,
667
]
],
[
[
1528,
24,
830
],
[
830,
63,
667
]
],
[
[
1528,
63,
104
],
[
104,
... | [
[
[
"Physostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Physostigmine",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is cau... | Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Solifenacin
Physostigmine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Solifenacin (Compound)
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Solifenacin
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Solifenacin
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Solifenacin
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Solifenacin
Physostigmine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Benazepril (Compound) and Benazepril (Compound) resembles Solifenacin (Compound)
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine (Compound) resembles Methdilazine (Compound) and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Solifenacin
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Mequitazine (Compound) and Mequitazine (Compound) resembles Solifenacin (Compound)
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Propantheline and Propantheline (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Solifenacin (Compound) |
DB00158 | DB00564 | 356 | 1,236 | [
"DDInter771",
"DDInter293"
] | Folic acid | Carbamazepine | Folic acid, also known as folate or Vitamin B9, is a member of the B vitamin family and an essential cofactor for enzymes involved in DNA and RNA synthesis. More specifically, folic acid is required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein. Folic acid is particularly important during phases of rapid cell division, such as infancy, pregnancy, and erythropoiesis, and plays a protective factor in the development of cancer. As humans are unable to synthesize folic acid endogenously, diet and supplementation is necessary to prevent deficiencies. For example, folic acid is present in green vegetables, beans, avocado, and some fruits. In order to function within the body, folic acid must first be reduced by the enzyme dihydrofolate reductase (DHFR) into the cofactors dihydrofolate (DHF) and tetrahydrofolate (TH | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbamazepine was the first anticonvulsant used to treat individuals with bipolar disorder. | Moderate | 1 | [
[
[
356,
24,
1236
]
],
[
[
356,
24,
362
],
[
362,
1,
1236
]
],
[
[
356,
24,
1335
],
[
1335,
40,
1236
]
],
[
[
356,
21,
28695
],
[
28695,
... | [
[
[
"Folic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
]
],
[
[
"Folic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
... | Folic acid may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Carbamazepine (Compound)
Folic acid may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine (Compound) resembles Carbamazepine (Compound)
Folic acid (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Carbamazepine (Compound)
Folic acid (Compound) resembles Methotrexate (Compound) and Folic acid may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine
Folic acid (Compound) resembles Leucovorin (Compound) and Leucovorin may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine
Folic acid may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Modafinil (Compound) and Modafinil (Compound) resembles Carbamazepine (Compound)
Folic acid may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine (Compound) resembles Magnesium salicylate (Compound) and Magnesium salicylate (Compound) resembles Carbamazepine (Compound)
Folic acid (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Modafinil (Compound) and Modafinil (Compound) resembles Carbamazepine (Compound)
Folic acid (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Magnesium salicylate (Compound) and Magnesium salicylate (Compound) resembles Carbamazepine (Compound) |
DB00047 | DB09082 | 176 | 659 | [
"DDInter932",
"DDInter1934"
] | Insulin glargine | Vilanterol | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis. Insulin is an important treatment in the management of Type 1 Diabetes (T1D), which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds with the (R)-configuration. Vilanterol is 1000 and 400 fold more selective for β2 than β1 and β3 adrenoceptors, respectively, with a faster onset of action than salmeterol. Additionally, vilanterol demonstrated a significantly longer duration of action than salmeterol, with the bronchodilator effect still apparent at 22h. Vilanterol's pharmacological effect is attributable to stimulation of intracellular adenylyl cyclase which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increases in cyclic AMP are associated with the relaxation of bronchial smooth muscle and inhibition of the release of hypersensitivity mediators from mast cells in the lungs.[A7738,A259961] Vilanterol is approved for use in several combination products such as with [fluticasone furoate] under the tradename BREO ELLIPTA, with [umeclidinium bromide] as ANORO ELLIPTA, and with both [fluticasone furoate] and [umeclidinium bromide] under the trade name TRELEGY ELLIPTA.[L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020.[L46876,L46881,L46886] Although all 3 products are approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD), only TRELEGY ELLIPTA and BREO ELLIPTA are approved for maintenance treatments of asthma in patients aged 18 years and older and 5 years and older respectively.[L46481,L44461,L44456] | Moderate | 1 | [
[
[
176,
24,
659
]
],
[
[
176,
24,
1220
],
[
1220,
23,
659
]
],
[
[
176,
24,
88
],
[
88,
24,
659
]
],
[
[
176,
25,
839
],
[
839,
24,... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Insulin glargine may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Semaglutide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Vilanterol
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol and Carvedilol may lead to a major life threatening interaction when taken with Vilanterol
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol |
DB06700 | DB06704 | 643 | 247 | [
"DDInter511",
"DDInter952"
] | Desvenlafaxine | Iobenguane (I-131) | Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of adults with major depressive disorder (MDD).[L6016,A261271] MDD is a highly prevalent psychiatric disorder, with a lifetime prevalence estimate of 16% in the US alone and 12.8% in Europe. Although the exact mechanism of pathophysiology is still unknown, imbalances or deficiencies of monoamines have been heavily implicated, thus the rationale behind the use of SNRI to treat MDD. Desvenlafaxine has a very similar pharmacological, efficacy, and safety profile as [ | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Major | 2 | [
[
[
643,
37,
247
]
],
[
[
643,
6,
7390
],
[
7390,
45,
247
]
],
[
[
643,
21,
28787
],
[
28787,
60,
247
]
],
[
[
643,
63,
820
],
[
820,
... | [
[
[
"Desvenlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Desvenlafaxine",
"{u} (Compound) binds {v} (Gene)",
... | Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Desvenlafaxine may lead to a major life threatening interaction when taken with Iobenguane
Desvenlafaxine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Iobenguane (Compound)
Desvenlafaxine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Iobenguane (Compound)
Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane
Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline and Tetryzoline may lead to a major life threatening interaction when taken with Iobenguane
Desvenlafaxine may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Iobenguane
Desvenlafaxine may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Iobenguane
Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Xylometazoline and Xylometazoline may lead to a major life threatening interaction when taken with Iobenguane
Desvenlafaxine (Compound) resembles Venlafaxine (Compound) and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Venlafaxine may lead to a major life threatening interaction when taken with Iobenguane
Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Pseudoephedrine may lead to a major life threatening interaction when taken with Iobenguane |
DB00254 | DB01575 | 964 | 1,054 | [
"DDInter598",
"DDInter1005"
] | Doxycycline | Kaolin | Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria. | Kaolin is a layered silicate mineral. Kaolin is used in ceramics, medicine, coated paper, as a food additive, in toothpaste, as a light diffusing material in white incandescent light bulbs, and in cosmetics. Until the early 1990s it was the active substance of anti-diarrhoea medicine Kaopectate. | Moderate | 1 | [
[
[
964,
24,
1054
]
],
[
[
964,
40,
1620
],
[
1620,
24,
1054
]
],
[
[
964,
24,
1252
],
[
1252,
24,
1054
]
],
[
[
964,
1,
1669
],
[
1669,
... | [
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kaolin"
]
],
[
[
"Doxycycline",
"{u} (Compound) resembles {v} (Compound)",
"Tetracycline"
],
[
"Tetracycline",
"{u} may cause a moder... | Doxycycline (Compound) resembles Tetracycline (Compound) and Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Kaolin
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Kaolin
Doxycycline (Compound) resembles Minocycline (Compound) and Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Kaolin
Doxycycline (Compound) resembles Tetracycline (Compound) and Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Kaolin
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Kaolin
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline and Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Kaolin
Doxycycline (Compound) resembles Minocycline (Compound) and Minocycline (Compound) resembles Tetracycline (Compound) and Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Kaolin
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Sotalol and Sotalol may cause a minor interaction that can limit clinical effects when taken with Kaolin
Doxycycline (Compound) resembles Tetracycline (Compound) and Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a moderate interaction that could exacerbate diseases when taken with Kaolin |
DB00188 | DB00776 | 168 | 1,335 | [
"DDInter222",
"DDInter1360"
] | Bortezomib | Oxcarbazepine | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib. Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exists as a racemate in the blood - a pro-drug of the more active (S)-enantiomer is also marketed as a separate anti-epileptic under the name [eslicarbazepine]. Compared to other anti-epileptic drugs, which are generally metabolized via the cytochrome P450 system, oxcarbazepine has a reduced propensity for involvement in drug-drug interactions owing to its primarily reductive metabolism. | Minor | 0 | [
[
[
168,
23,
1335
]
],
[
[
168,
23,
126
],
[
126,
1,
1335
]
],
[
[
168,
25,
1236
],
[
1236,
1,
1335
]
],
[
[
168,
23,
902
],
[
902,
... | [
[
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Oxcarbazepine"
]
],
[
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
... | Bortezomib may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin (Compound) resembles Oxcarbazepine (Compound)
Bortezomib may lead to a major life threatening interaction when taken with Carbamazepine and Carbamazepine (Compound) resembles Oxcarbazepine (Compound)
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Clobazam and Clobazam (Compound) resembles Oxcarbazepine (Compound)
Bortezomib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Oxcarbazepine (Compound)
Bortezomib (Compound) causes Multiple fractures (Side Effect) and Multiple fractures (Side Effect) is caused by Oxcarbazepine (Compound)
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Oxcarbazepine
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine |
DB00694 | DB11986 | 51 | 484 | [
"DDInter485",
"DDInter648"
] | Daunorubicin | Entrectinib | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets. | Moderate | 1 | [
[
[
51,
24,
484
]
],
[
[
51,
23,
1247
],
[
1247,
23,
484
]
],
[
[
51,
24,
466
],
[
466,
62,
484
]
],
[
[
51,
24,
1539
],
[
1539,
24,... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Daunorubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],... | Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin and Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Daunorubicin (Compound) resembles Epirubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Galantamine and Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine and Oliceridine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Daunorubicin (Compound) resembles Idarubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Daunorubicin may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib |
DB01254 | DB14783 | 1,213 | 287 | [
"DDInter484",
"DDInter574"
] | Dasatinib | Diroximel fumarate | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting forms of MS lead to neurological symptoms that resolve and recur periodically. More than 80% of patients suffering from this disease have relapsing-remitting MS. Diroximel fumarate is a new drug from the fumarate class formulated to treat various relapsing forms of MS. This drug is bioequivalent to [Dimethyl fumarate][A187544,L9626](initially manufactured in 2013), but is less likely to cause gastrointestinal side effects, owing to its unique chemical structure. Diroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA in October 2019 and by the EMA in November 2021. | Moderate | 1 | [
[
[
1213,
24,
287
]
],
[
[
1213,
63,
1101
],
[
1101,
24,
287
]
],
[
[
1213,
25,
384
],
[
384,
24,
287
]
],
[
[
1213,
64,
1220
],
[
1220,
... | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Dasatinib may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Dasatinib may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Dasatinib may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Diroximel fumarate
Dasatinib may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Diroximel fumarate
Dasatinib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Diroximel fumarate
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may lead to a major life threatening interaction when taken with Diroximel fumarate
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate |
DB04837 | DB09118 | 649 | 1,580 | [
"DDInter407",
"DDInter1711"
] | Clofedanol | Stiripentol | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzymes. However, its clinical efficacy as adjunctive therapy for epilepsies stems from its inhibitory action on CYP enzymes, as stiripentol reduces the degradation of CYP-sensitive antiepileptic drugs, hence boosting their therapeutic efficacy. Stiripentol may also exhibit direct anticonvulsant properties, although the exact mechanism of action is fully understood. Approved in the US, Canada, and Europe, stiripentol is used to treat seizures associated with Dravet syndrome.[L880,L42500,L42510] It is marketed under the brand name Diacomit. | Moderate | 1 | [
[
[
649,
24,
1580
]
],
[
[
649,
24,
1609
],
[
1609,
63,
1580
]
],
[
[
649,
63,
1688
],
[
1688,
24,
1580
]
],
[
[
649,
1,
820
],
[
820,
... | [
[
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
],
... | Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate and Diphenoxylate may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Clofedanol (Compound) resembles Alimemazine (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Clofedanol (Compound) resembles Carbinoxamine (Compound) and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Clofedanol (Compound) resembles Toremifene (Compound) and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Clofedanol (Compound) resembles Tamoxifen (Compound) and Tamoxifen may lead to a major life threatening interaction when taken with Stiripentol
Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol |
DB00488 | DB06688 | 196 | 1,430 | [
"DDInter57",
"DDInter1677"
] | Altretamine | Sipuleucel-T | An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects. | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared specifically for each patient. In metastatic prostate cancer, it has extended survival by median 4.1 months (IMPACT Phase III trial data). Sipuleucel-T is marketed under the brand name Provenge by Dendreon Corporation. Sipuleucel-T was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic Hormone-Refractory Prostate Cancer (HRPC). The treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014. | Moderate | 1 | [
[
[
196,
24,
1430
]
],
[
[
196,
24,
869
],
[
869,
24,
1430
]
],
[
[
196,
25,
676
],
[
676,
63,
1430
]
],
[
[
196,
24,
713
],
[
713,
... | [
[
[
"Altretamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Altretamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[... | Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Altretamine may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Altretamine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Altretamine may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Altretamine may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Sipuleucel-T
Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Altretamine may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T |
DB06186 | DB12364 | 1,439 | 1,421 | [
"DDInter969",
"DDInter200"
] | Ipilimumab | Betrixaban | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approval on 25 March 2011. | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks for VTE . VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients . | Major | 2 | [
[
[
1439,
25,
1421
]
],
[
[
1439,
24,
637
],
[
637,
24,
1421
]
],
[
[
1439,
25,
990
],
[
990,
24,
1421
]
],
[
[
1439,
63,
305
],
[
305,
... | [
[
[
"Ipilimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
],
... | Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi and Asparaginase Erwinia chrysanthemi may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Ipilimumab may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol and Calaspargase pegol may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone may lead to a major life threatening interaction when taken with Betrixaban
Ipilimumab may lead to a major life threatening interaction when taken with Desirudin and Desirudin may lead to a major life threatening interaction when taken with Betrixaban
Ipilimumab may lead to a major life threatening interaction when taken with Argatroban and Argatroban may lead to a major life threatening interaction when taken with Betrixaban
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may lead to a major life threatening interaction when taken with Betrixaban
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi and Asparaginase Erwinia chrysanthemi may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban |
DB00731 | DB04868 | 1,144 | 478 | [
"DDInter1269",
"DDInter1293"
] | Nateglinide | Nilotinib | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML. | Moderate | 1 | [
[
[
1144,
24,
478
]
],
[
[
1144,
6,
6017
],
[
6017,
45,
478
]
],
[
[
1144,
21,
28966
],
[
28966,
60,
478
]
],
[
[
1144,
24,
1247
],
[
1247... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Nateglinide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)"... | Nateglinide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Nateglinide (Compound) causes Upper respiratory tract infection (Side Effect) and Upper respiratory tract infection (Side Effect) is caused by Nilotinib (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Nilotinib
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Nateglinide (Compound) resembles Amphetamine (Compound) and Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Nateglinide may cause a minor interaction that can limit clinical effects when taken with Sulfinpyrazone and Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Nateglinide may cause a minor interaction that can limit clinical effects when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib |
DB06212 | DB14568 | 165 | 982 | [
"DDInter1833",
"DDInter1000"
] | Tolvaptan | Ivosidenib | Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009. | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults. It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma and relapsed or refractory myelodysplastic syndromes in adults. The drug is only effective in patients with a susceptible IDH1 mutation. In February 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of ivosidenib and recommended it be granted marketing authorization for the treatment of acute myeloid leukemia and cholangiocarcinoma. It was fully approved by the EMA in May 2023. | Moderate | 1 | [
[
[
165,
24,
982
]
],
[
[
165,
63,
1101
],
[
1101,
23,
982
]
],
[
[
165,
63,
543
],
[
543,
24,
982
]
],
[
[
165,
23,
1135
],
[
1135,
... | [
[
[
"Tolvaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Tolvaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Tolvaptan may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may lead to a major life threatening interaction when taken with Ivosidenib
Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Ivosidenib
Tolvaptan may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Ivosidenib
Tolvaptan may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Ivosidenib |
DB01268 | DB01320 | 1,151 | 651 | [
"DDInter1731",
"DDInter783"
] | Sunitinib | Fosphenytoin | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials. | Major | 2 | [
[
[
1151,
25,
651
]
],
[
[
1151,
63,
307
],
[
307,
1,
651
]
],
[
[
1151,
64,
362
],
[
362,
1,
651
]
],
[
[
1151,
6,
8374
],
[
8374,
... | [
[
[
"Sunitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
"Modafinil",... | Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil (Compound) resembles Fosphenytoin (Compound)
Sunitinib may lead to a major life threatening interaction when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
Sunitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fosphenytoin (Compound)
Sunitinib (Compound) causes Face oedema (Side Effect) and Face oedema (Side Effect) is caused by Fosphenytoin (Compound)
Sunitinib may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Fosphenytoin
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Sunitinib may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Sunitinib (Compound) resembles Metoclopramide (Compound) and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin |
DB00197 | DB00959 | 1,324 | 1,486 | [
"DDInter1881",
"DDInter1191"
] | Troglitazone | Methylprednisolone | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression. The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials. | Moderate | 1 | [
[
[
1324,
24,
1486
]
],
[
[
1324,
24,
175
],
[
175,
40,
1486
]
],
[
[
1324,
24,
167
],
[
167,
1,
1486
]
],
[
[
1324,
24,
1072
],
[
1072,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Methylprednisolone (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may cause a minor interaction that can limit clinical effects when taken with Methylprednisolone
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a minor interaction that can limit clinical effects when taken with Methylprednisolone
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Mestranol and Mestranol may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone
Troglitazone may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin may lead to a major life threatening interaction when taken with Methylprednisolone |
DB01406 | DB11730 | 984 | 351 | [
"DDInter472",
"DDInter1588"
] | Danazol | Ribociclib | A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali. | Moderate | 1 | [
[
[
984,
24,
351
]
],
[
[
984,
62,
222
],
[
222,
23,
351
]
],
[
[
984,
1,
1561
],
[
1561,
24,
351
]
],
[
[
984,
63,
372
],
[
372,
24... | [
[
[
"Danazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Danazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"Si... | Danazol may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Danazol (Compound) resembles Testosterone (Compound) and Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Danazol may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Danazol may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Danazol (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Danazol may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Danazol may lead to a major life threatening interaction when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Danazol may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Ribociclib
Danazol may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may lead to a major life threatening interaction when taken with Ribociclib |
DB06317 | DB09122 | 1,626 | 1,613 | [
"DDInter630",
"DDInter1409"
] | Elotuzumab | Peginterferon beta-1a | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks. Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration. Elotuzumab | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792] Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021. Currently, it is the only approved pegylated interferon for the management of MS with an proven ability to reduce relapses and delay the progression of disability resulting from MS. | Moderate | 1 | [
[
[
1626,
24,
1613
]
],
[
[
1626,
63,
671
],
[
671,
24,
1613
]
],
[
[
1626,
24,
1627
],
[
1627,
24,
1613
]
],
[
[
1626,
24,
287
],
[
287,
... | [
[
[
"Elotuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Elotuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
... | Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate and Diroximel fumarate may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Elotuzumab may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Elotuzumab may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Elotuzumab may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Peginterferon beta-1a
Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may lead to a major life threatening interaction when taken with Peginterferon beta-1a
Elotuzumab may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may lead to a major life threatening interaction when taken with Peginterferon beta-1a
Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a |
DB00280 | DB00938 | 494 | 455 | [
"DDInter575",
"DDInter1635"
] | Disopyramide | Salmeterol | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. Salmeterol was granted FDA approval on 4 February 1994. | Moderate | 1 | [
[
[
494,
24,
455
]
],
[
[
494,
24,
688
],
[
688,
63,
455
]
],
[
[
494,
6,
8374
],
[
8374,
45,
455
]
],
[
[
494,
21,
28722
],
[
28722,
... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
... | Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Disopyramide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Salmeterol (Compound)
Disopyramide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Salmeterol (Compound)
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Salmeterol
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Salmeterol
Disopyramide may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Disopyramide may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol |
DB01042 | DB01206 | 1,307 | 37 | [
"DDInter1144",
"DDInter1086"
] | Melphalan | Lomustine | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases. | An alkylating agent of value against both hematologic malignancies and solid tumors. | Moderate | 1 | [
[
[
1307,
24,
37
]
],
[
[
1307,
5,
11555
],
[
11555,
44,
37
]
],
[
[
1307,
54,
19138
],
[
19138,
15,
37
]
],
[
[
1307,
21,
28722
],
[
2872... | [
[
[
"Melphalan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
]
],
[
[
"Melphalan",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease) ... | Melphalan (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Lomustine (Compound)
Melphalan (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Lomustine (Compound)
Melphalan (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Lomustine (Compound)
Melphalan may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Lomustine
Melphalan may cause a minor interaction that can limit clinical effects when taken with Delafloxacin and Delafloxacin may cause a minor interaction that can limit clinical effects when taken with Lomustine
Melphalan may cause a minor interaction that can limit clinical effects when taken with Norfloxacin and Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Lomustine
Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a minor interaction that can limit clinical effects when taken with Lomustine
Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim and Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Lomustine
Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride and Radium Ra 223 dichloride may cause a moderate interaction that could exacerbate diseases when taken with Lomustine |
DB00835 | DB09420 | 100 | 1,074 | [
"DDInter245",
"DDInter953"
] | Brompheniramine | Iodide I-123 | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect the decay by electron capture to tellurium-123. Iodine is commonly used in thyroid function diagnostic tests as this gland normally absorbs iodine through the diet for formation of the thyroid hormones triiodothyronine (T3) and its prohormone, thyroxine (T4). Radioactive I-123 in particular is effective for this use as its half-life of approximately 13.13 h (hours) is ideal for the 24-h (hour) iodine uptake test and it has a reduced radiation burden as compared to I-131. | Moderate | 1 | [
[
[
100,
24,
1074
]
],
[
[
100,
24,
516
],
[
516,
24,
1074
]
],
[
[
100,
35,
849
],
[
849,
24,
1074
]
],
[
[
100,
63,
902
],
[
902,
... | [
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"... | Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Brompheniramine (Compound) resembles Mepyramine (Compound) and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Brompheniramine (Compound) resembles Carbinoxamine (Compound) and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Brompheniramine (Compound) resembles Mepyramine (Compound) and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 |
DB00443 | DB00912 | 251 | 473 | [
"DDInter195",
"DDInter1581"
] | Betamethasone | Repaglinide | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity. | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Repaglinide is extensively metabolized in the liver and excreted in bile. Repaglinide metabolites do not possess appreciable hypoglycemic activity. Approximately 90% of a single orally administered dose is eliminated in feces and 8% in urine. | Moderate | 1 | [
[
[
251,
24,
473
]
],
[
[
251,
6,
8374
],
[
8374,
45,
473
]
],
[
[
251,
18,
5245
],
[
5245,
57,
473
]
],
[
[
251,
21,
28876
],
[
28876,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Betamethasone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Comp... | Betamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Repaglinide (Compound)
Betamethasone (Compound) downregulates DNMT3A (Gene) and DNMT3A (Gene) is downregulated by Repaglinide (Compound)
Betamethasone (Compound) causes Anaphylactoid reaction (Side Effect) and Anaphylactoid reaction (Side Effect) is caused by Repaglinide (Compound)
Betamethasone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Repaglinide
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Oxandrolone and Oxandrolone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Betamethasone may lead to a major life threatening interaction when taken with Bempedoic acid and Bempedoic acid may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Betamethasone may cause a minor interaction that can limit clinical effects when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide |
DB01124 | DB01377 | 1,411 | 1,283 | [
"DDInter1828",
"DDInter1119"
] | Tolbutamide | Magnesium oxide | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Moderate | 1 | [
[
[
1411,
24,
1283
]
],
[
[
1411,
63,
743
],
[
743,
23,
1283
]
],
[
[
1411,
24,
1592
],
[
1592,
62,
1283
]
],
[
[
1411,
24,
772
],
[
772,
... | [
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisinopril"
],
... | Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Lisinopril and Lisinopril may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Nebivolol and Nebivolol may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol and Carvedilol may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Valproic acid and Valproic acid may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Tolbutamide may lead to a major life threatening interaction when taken with Delafloxacin and Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide
Tolbutamide may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide
Tolbutamide may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide |
DB00673 | DB09048 | 723 | 555 | [
"DDInter112",
"DDInter1284"
] | Aprepitant | Netupitant | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV). | Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc. under the brand Akynzeo. | Moderate | 1 | [
[
[
723,
24,
555
]
],
[
[
723,
62,
1101
],
[
1101,
23,
555
]
],
[
[
723,
23,
466
],
[
466,
62,
555
]
],
[
[
723,
24,
283
],
[
283,
6... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
]
],
[
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
... | Aprepitant may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Netupitant
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Netupitant
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Netupitant
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Netupitant
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Netupitant
Aprepitant may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Netupitant
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Netupitant
Aprepitant may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may lead to a major life threatening interaction when taken with Netupitant
Aprepitant may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may lead to a major life threatening interaction when taken with Netupitant |
DB00652 | DB01156 | 234 | 593 | [
"DDInter1421",
"DDInter252"
] | Pentazocine | Bupropion | The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97) | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the uptake of the neurotransmitters norepinephrine and dopamine from the synaptic cleft, therefore prolonging their duration of action within the neuronal synapse and the downstream effects of these neurotransmitters. More specifically, bupropion binds to the norepinephrine transporter (NET) and the dopamine transporter (DAT).[A6399,A178810] Bupropion was originally classified as an "atypical" antidepressant because it does not exert the same effects as the classical antidepressants such as Monoamine Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants (TCAs), or Selective Serotonin Reuptake Inhibitors (SSRIs). While it has comparable effectiveness to typical first-line options for the treatment of depression such as SSRIs,[A178798,A178804] bupropion is a unique option for the treatment of MDD as it lacks any clinically relevant serotonergic effects, typical of other mood medications, or any effects on histamine or adrenaline receptors.[A6399,A178840] Lack of activity at these receptors results in a more tolerable side effect profile; bupropion is less likely to cause sexual side effects, sedation, or weight gain as compared to SSRIs or TCAs, for example.[A178804,A178807] When used as an aid to smoking cessation, bupropion is thought to confer its anti-craving and anti-withdrawal effects by inhibiting dopamine reuptake, which is thought to be involved in the reward pathways associated with nicotine, and through the antagonism of the nicotinic acetylcholinergic receptor.[A178825,A1966,A16508] A Cochrane Review of meta-analyses of available treatment modalities for smoking cessation found that abstinence rates approximately doubled when bupropion was used as compared to placebo, and was found to have similar rates of smoking cessation as [nicotine] replacement therapy (NRT). Bupropion is sometimes used as an add-on agent to first-line treatments of depression such as selective serotonin reuptake inhibitor (SSRI) medications when there is a treatment-failure or only partial response. Bupropion is also used off-label for the management of Attention/Deficit-Hyperactivity Disorder (ADHD) in adults with comorbid bipolar depression to avoid mood destabilization caused by typical stimulant medications used for the treatment of ADHD. When used in combination with [naltrexone] in the marketed product ContraveⓇ for chronic weight management, the two components are thought to have effects on areas of the brain involved in the regulation of food intake. This includes the hypothalamus, which is involved in appetite regulation, and the mesolimbic dopamine circuit, which is involved in reward pathways. Studies have shown that the combined activity of bupropion and [naltrexone] increase the firing rate of hypothalamic pro-opiomelanocortin (POMC) neurons and blockade of opioid receptor-mediated POMC auto-inhibition, which are associated with a reduction in food intake and increased energy expenditure.[L6562,A179038,A179050] The combination of naltrexone and bupropion was shown to result in a statistically significant weight loss, with a mean change in body weight of -6.3% compared to -1.3% for placebo. | Major | 2 | [
[
[
234,
25,
593
]
],
[
[
234,
21,
28905
],
[
28905,
60,
593
]
],
[
[
234,
24,
256
],
[
256,
62,
593
]
],
[
[
234,
63,
752
],
[
752,
... | [
[
[
"Pentazocine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
]
],
[
[
"Pentazocine",
"{u} (Compound) causes {v} (Side Effect)",
"Irritability"
],
[
"Irritability",
"{u} (Side Effect) is caused by {v... | Pentazocine (Compound) causes Irritability (Side Effect) and Irritability (Side Effect) is caused by Bupropion (Compound)
Pentazocine may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Bupropion
Pentazocine may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Bupropion
Pentazocine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Bupropion
Pentazocine may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil and Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Bupropion
Pentazocine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Bupropion
Pentazocine may lead to a major life threatening interaction when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Bupropion
Pentazocine may cause a moderate interaction that could exacerbate diseases when taken with Lindane and Lindane may lead to a major life threatening interaction when taken with Bupropion
Pentazocine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may lead to a major life threatening interaction when taken with Bupropion |
DB01115 | DB11718 | 336 | 927 | [
"DDInter1291",
"DDInter640"
] | Nifedipine | Encorafenib | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action. The most popular of the third generation dihydropyridines is [amlodipine]. Nifedipine was granted FDA approval on 31 December 1981. | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung. On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. | Moderate | 1 | [
[
[
336,
24,
927
]
],
[
[
336,
63,
1324
],
[
1324,
24,
927
]
],
[
[
336,
40,
84
],
[
84,
24,
927
]
],
[
[
336,
24,
1491
],
[
1491,
2... | [
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[... | Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Nifedipine (Compound) resembles Nisoldipine (Compound) and Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Nifedipine (Compound) resembles Nicardipine (Compound) and Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Nifedipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Nifedipine may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Encorafenib
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Encorafenib |
DB01211 | DB09043 | 609 | 135 | [
"DDInter393",
"DDInter36"
] | Clarithromycin | Albiglutide | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration. | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA. | Moderate | 1 | [
[
[
609,
24,
135
]
],
[
[
609,
64,
126
],
[
126,
23,
135
]
],
[
[
609,
63,
1647
],
[
1647,
23,
135
]
],
[
[
609,
24,
519
],
[
519,
2... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"War... | Clarithromycin may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Fosamprenavir and Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan and Somapacitan may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide
Clarithromycin may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide
Clarithromycin may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide
Clarithromycin may lead to a major life threatening interaction when taken with Saquinavir and Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide |
DB00876 | DB09268 | 1,414 | 1,662 | [
"DDInter658",
"DDInter1464"
] | Eprosartan | Picosulfuric acid | Eprosartan is an angiotensin II receptor antagonist used to treat hypertension. It performs 2 actions on the renin angiotensin system. By preventing the binding of angiotensin II to AT1, vascular smooth muscle relaxes and vasodilation occurs. By inhibiting norepinephrine production, blood pressure is further reduced. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years. | Moderate | 1 | [
[
[
1414,
24,
1662
]
],
[
[
1414,
24,
708
],
[
708,
24,
1662
]
],
[
[
1414,
63,
1573
],
[
1573,
24,
1662
]
],
[
[
1414,
24,
407
],
[
407,
... | [
[
[
"Eprosartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Eprosartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]... | Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Eprosartan (Compound) resembles Losartan (Compound) and Losartan may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Methazolamide and Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid
Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Trimipramine (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a minor interaction that can limit clinical effects when taken with Linaclotide and Linaclotide may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid
Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a minor interaction that can limit clinical effects when taken with Linaclotide and Linaclotide may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid |
DB00041 | DB01359 | 1,648 | 729 | [
"DDInter38",
"DDInter1417"
] | Aldesleukin | Penbutolol | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125. | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high binding affinity to the 5-hydroxytryptamine receptor 1A with antagonistic effects. This binding characteristic of penbutolol is being investigated for its implications in Antidepressant Therapy. Penbutolol is contraindicated in patients with cardiogenic shock, sinus bradycardia, second and third degree atrioventricular conduction block, bronchial asthma, and those with known hypersensitivity. | Moderate | 1 | [
[
[
1648,
24,
729
]
],
[
[
1648,
24,
461
],
[
461,
1,
729
]
],
[
[
1648,
24,
699
],
[
699,
40,
729
]
],
[
[
1648,
24,
552
],
[
552,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol (Compound) resembles Penbutolol (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol (Compound) resembles Penbutolol (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may cause a minor interaction that can limit clinical effects when taken with Penbutolol
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iopromide and Iopromide may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol
Aldesleukin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol
Aldesleukin may lead to a major life threatening interaction when taken with Iohexol and Iohexol may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol
Aldesleukin may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Penbutolol
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol (Compound) resembles Bupranolol (Compound) and Bupranolol (Compound) resembles Penbutolol (Compound) |
DB00820 | DB01240 | 402 | 885 | [
"DDInter1736",
"DDInter657"
] | Tadalafil | Epoprostenol | Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy.[L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibitors like [sildenafil], tadalafil has greater selectivity for PDE5 and a longer half-life which has made it a more suitable option for chronic once-daily dosing in the treatment of PAH. | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Minor | 0 | [
[
[
402,
23,
885
]
],
[
[
402,
62,
1061
],
[
1061,
1,
885
]
],
[
[
402,
10,
11573
],
[
11573,
49,
885
]
],
[
[
402,
21,
28684
],
[
28684,
... | [
[
[
"Tadalafil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Epoprostenol"
]
],
[
[
"Tadalafil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Treprostinil"
],
[
... | Tadalafil may cause a minor interaction that can limit clinical effects when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Tadalafil (Compound) palliates systemic scleroderma (Disease) and systemic scleroderma (Disease) is palliated by Epoprostenol (Compound)
Tadalafil (Compound) causes Hypoaesthesia (Side Effect) and Hypoaesthesia (Side Effect) is caused by Epoprostenol (Compound)
Tadalafil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Tadalafil may lead to a major life threatening interaction when taken with Amyl Nitrite and Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Tadalafil may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Tadalafil may cause a minor interaction that can limit clinical effects when taken with Minoxidil and Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Tadalafil may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine and Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Tadalafil may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may lead to a major life threatening interaction when taken with Epoprostenol |
DB00673 | DB01149 | 723 | 851 | [
"DDInter112",
"DDInter1274"
] | Aprepitant | Nefazodone | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV). | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with the incidence of severe liver damage was shown to be approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. | Moderate | 1 | [
[
[
723,
24,
851
]
],
[
[
723,
24,
673
],
[
673,
40,
851
]
],
[
[
723,
63,
827
],
[
827,
40,
851
]
],
[
[
723,
6,
8374
],
[
8374,
45... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
],
[
... | Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole and Aripiprazole (Compound) resembles Nefazodone (Compound)
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Nefazodone (Compound)
Aprepitant (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nefazodone (Compound)
Aprepitant (Compound) causes Dysuria (Side Effect) and Dysuria (Side Effect) is caused by Nefazodone (Compound)
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Nefazodone
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Nefazodone
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone |
DB00655 | DB11979 | 559 | 1,320 | [
"DDInter682",
"DDInter625"
] | Estrone | Elagolix | Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion of adrostenedione. Estrone may be further metabolized to 16-alpha-hydroxyestrone, which may be reduced to estriol by estradiol dehydrogenase. | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain . It has been determined that endometriosis is one of the most common gynecologic disorders in the United States [A35868, A35869, F801]. In particular, estimates suggest that one in ten women of reproductive age is affected by endometriosis and experience debilitating pain symptoms [A35868, A35869, F801]. Moreover, women who are affected by this condition can suffer for up to six to ten years and visit multiple physicians before receiving a proper diagnosis [A35868, A35869, F801]. Subsequently, as Orilissa (elagolix) was approved by the FDA under priority review , this expedited new approval gives healthcare professionals another valuable option for treating the potentially unmet needs of women who are affected by endometriosis, depending on their specific type and severity of endometriosis pain. | Moderate | 1 | [
[
[
559,
24,
1320
]
],
[
[
559,
24,
129
],
[
129,
24,
1320
]
],
[
[
559,
24,
159
],
[
159,
63,
1320
]
],
[
[
559,
1,
35
],
[
35,
24,... | [
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"E... | Estrone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Estrone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Estrone (Compound) resembles Quinestrol (Compound) and Quinestrol may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Estrone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Estrone may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Estrone may lead to a major life threatening interaction when taken with Lenalidomide and Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Estrone (Compound) resembles Estradiol (Compound) and Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Estrone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Elagolix
Estrone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix |
DB00041 | DB00999 | 1,648 | 504 | [
"DDInter38",
"DDInter883"
] | Aldesleukin | Hydrochlorothiazide | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125. | Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors[L8390,L8423] or angiotensin II receptor blockers.[L7426,L7459] Hydrochlorothiazide was granted FDA approval on 12 February 1959. | Moderate | 1 | [
[
[
1648,
24,
504
]
],
[
[
1648,
24,
1326
],
[
1326,
40,
504
]
],
[
[
1648,
24,
178
],
[
178,
1,
504
]
],
[
[
1648,
24,
1264
],
[
1264,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenamide"
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Diclofenamide and Diclofenamide (Compound) resembles Hydrochlorothiazide (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide and Polythiazide (Compound) resembles Hydrochlorothiazide (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide
Aldesleukin may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Diclofenamide and Diclofenamide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide (Compound) resembles Hydrochlorothiazide (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Bendroflumethiazide and Bendroflumethiazide (Compound) resembles Polythiazide (Compound) and Polythiazide (Compound) resembles Hydrochlorothiazide (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound) resembles Diclofenamide (Compound) and Diclofenamide (Compound) resembles Hydrochlorothiazide (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide and Polythiazide (Compound) resembles Hydrochlorothiazide (Compound) |
DB00903 | DB09564 | 1,680 | 1,296 | [
"DDInter686",
"DDInter930"
] | Etacrynic acid | Insulin degludec | A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic. | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism.[A18561,A18562,A18563,A18564,A174934] Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle.[A18561,A18562,A18563,A18564,A174934] Absorption of glucose into cells allows for its transformation into glycogen or fat for storage.[A18561,A18562,A18563,A18564,A174934] Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions.[A18561,A18562,A18563,A18564,A174934] Insulin is an essential treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels.[A18561,A18562,A18563,A18564,A174934] As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin degludec, to lower glucose levels in the blood.[A18561,A18562,A18563,A18564,A174934] Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels.[A18561,A18562,A18563,A18564,A174934] Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed later in the course of T2D, after several oral medications such as , , or have been tried, when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own.[A18561,A18562,A18563,A18564,A174934] Marketed as the brand name product Tresiba, insulin degludec has a duration of action up to 42 hours allowing for once-daily dosing, typically at bedtime.[A18561,A18562,A18563,A18564,A174934] Due to its duration of action, Tresiba is considered "basal insulin" as it provides low concentrations of background insulin that can keep blood sugar stable between meals or overnight.[A18561,A18562,A18563,A18564,A174934] Basal insulin is often combined with short-acting "bolus insulin" such as , , or to provide higher doses of insulin required following meals. Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with the goal of avoiding any periods of hypoglycemia.[A18561,A18562,A18563,A18564,A174934] Compared to endogenous insulin, insulin degludec has an added hexadecanedioic acid on lysine at the B29 position, allowing for the formation of multi-hexamers.[A18561,A18562,A18563,A18564,A174934] When injected subcutaneously, these multi-hexamers form a drug depot store from which monomers are slowly and continuously absorbed into circulation.[A18561,A18562,A18563,A18564,A174934] As a result, Insulin Degludec has a protracted time action profile due to the delayed absorption from subcutaneous tissue depots into the systemic circulation.[A18561,A18562,A18563,A18564,A174934] Compared to available long-acting analogs such as and , which have a duration of action of 20-24 hours, insulin degludec provides a consistent level of basal insulin over 42 hours with a low peak: trough ratio.[A18561,A18562,A18563,A18564,A174934] Limitations of shorter-acting analogs include more frequent dosing and less stable pharmacokinetics, which may negatively impact patient adherence and glucose control, particularly nocturnal control.[A18561,A18562,A18563,A18564,A174934] Without an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst.[A18561,A18562,A18563,A18564,A174934] If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy.[A18561,A18562,A18563,A18564,A174934] Insulin Degludec was approved by the FDA in September 2015 as the product Tresiba, for use in providing glycemic control to adults with diabetes mellitus. | Moderate | 1 | [
[
[
1680,
24,
1296
]
],
[
[
1680,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
1680,
63,
1645
],
[
1645,
24,
1296
]
],
[
[
1680,
62,
964
],
[
964... | [
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
... | Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Etacrynic acid may cause a minor interaction that can limit clinical effects when taken with Doxycycline and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Etacrynic acid may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Semaglutide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Insulin degludec
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may lead to a major life threatening interaction when taken with Sotalol and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Insulin degludec
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine and Phentolamine may cause a minor interaction that can limit clinical effects when taken with Insulin degludec |
DB06186 | DB09121 | 1,439 | 1,328 | [
"DDInter969",
"DDInter140"
] | Ipilimumab | Aurothioglucose | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approval on 25 March 2011. | Aurothioglucose, also known as gold thioglucose, was formerly used to treat rheumatoid arthritis. Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis . The use of gold compounds has decreased since the 1980s owing to numerous side effects, limited efficacy, and slow onset of action. Many if not most gold compounds that were indicated for rheumatoid arthritis therapy have since been replaced with the use of various current disease modifying anti-rheumatic drugs (DMARDs) like methotrexate and others, which are far more effective. | Moderate | 1 | [
[
[
1439,
24,
1328
]
],
[
[
1439,
63,
367
],
[
367,
24,
1328
]
],
[
[
1439,
24,
310
],
[
310,
24,
1328
]
],
[
[
1439,
24,
148
],
[
148,
... | [
[
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aurothioglucose"
]
],
[
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon alfacon-1"
... | Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole and Secnidazole may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Aurothioglucose
Ipilimumab may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Aurothioglucose
Ipilimumab may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Aurothioglucose
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose |
DB01192 | DB08895 | 560 | 976 | [
"DDInter1372",
"DDInter1825"
] | Oxymorphone | Tofacitinib | An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). On June 8, 2017, FDA requested Endo Pharmaceuticals to remove the medication from the market due to opioid misuse and abuse risks associated with the product's injectable reformulation. | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer. | Moderate | 1 | [
[
[
560,
24,
976
]
],
[
[
560,
40,
314
],
[
314,
24,
976
]
],
[
[
560,
24,
407
],
[
407,
63,
976
]
],
[
[
560,
75,
475
],
[
475,
24,... | [
[
[
"Oxymorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Oxymorphone",
"{u} (Compound) resembles {v} (Compound)",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may cause a mode... | Oxymorphone (Compound) resembles Nalbuphine (Compound) and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Oxymorphone (Compound) resembles Morphine (Compound) and Oxymorphone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may lead to a major life threatening interaction when taken with Tofacitinib
Oxymorphone may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Tofacitinib
Oxymorphone (Compound) resembles Nalbuphine (Compound) and Nalbuphine may lead to a major life threatening interaction when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Oxymorphone (Compound) resembles Morphine (Compound) and Oxymorphone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Oxymorphone (Compound) resembles Oxycodone (Compound) and Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib |
DB00252 | DB00471 | 362 | 201 | [
"DDInter1460",
"DDInter1242"
] | Phenytoin | Montelukast | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for several other indications such as bipolar disorder, retina protection, and wound healing.[A188826,A188832] Clinicians are advised to initiate therapeutic drug monitoring in patients who require phenytoin since even small deviations from the recommended therapeutic range can lead to suboptimal treatment, or adverse effects.[A189219,A35884] Both parenteral and oral formulations of phenytoin are available on the market. | Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Although capable of demonstrating effectiveness, the use of such LTRAs like montelukast is typically in addition to or complementary with the use of inhaled corticosteroids or other agents in asthma step therapy. Regardless, in 2008-2009, there were FDA-led investigations into the possibility of montelukast to elicit neuropsychiatric effects like agitation, hallucinations, suicidal behaviour, and others in individuals who used the medication. And although these kinds of effects are currently included in the official prescribing information for montelukast,[L6301,L6304,L6307,L6310,L6325,L6328,L6331] the drug still sees extensive use worldwide via millions of prescriptions annually and has since become available as a generic and as a brand name product. | Moderate | 1 | [
[
[
362,
24,
201
]
],
[
[
362,
6,
3486
],
[
3486,
45,
201
]
],
[
[
362,
7,
6952
],
[
6952,
46,
201
]
],
[
[
362,
21,
28787
],
[
28787,
... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Montelukast"
]
],
[
[
"Phenytoin",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
... | Phenytoin (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Montelukast (Compound)
Phenytoin (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Montelukast (Compound)
Phenytoin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Montelukast (Compound)
Phenytoin may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Montelukast
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Montelukast
Phenytoin (Compound) resembles Carbamazepine (Compound) and Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Montelukast
Phenytoin may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Montelukast
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Montelukast
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Montelukast |
DB05239 | DB11601 | 866 | 1,270 | [
"DDInter425",
"DDInter1889"
] | Cobimetinib | Tuberculin purified protein derivative | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma. | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycobacterium tuberculosis* through early diagnosis and appropriate therapeutic intervention. The purified protein fraction is isolated from culture media filtrates of a human strain of Mycobacterium tuberculosis. It is included in the World Health Organization's List of Essential Medicines. | Moderate | 1 | [
[
[
866,
24,
1270
]
],
[
[
866,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
866,
63,
869
],
[
869,
24,
1270
]
],
[
[
866,
64,
1064
],
[
1064,
... | [
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Cobimetinib may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Cobimetinib may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Cobimetinib may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Cobimetinib may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative |
DB00104 | DB06655 | 966 | 5 | [
"DDInter1323",
"DDInter1077"
] | Octreotide | Liraglutide | Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is a life-threatening disease requiring life-long management. Octreotide is a long-acting drug with pharmacologic activities that mimic those of the natural hormone, somatostatin, which inhibits the secretion of growth hormone. Additionally, it is used for the treatment of acromegaly and symptoms arising from various tumors, including carcinoid tumors and vasoactive intestinal tumors (VIPomas). In the past, octreotide has been administered solely by injection. On June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor. Liraglutide was granted FDA approval on January 25, 2010. | Moderate | 1 | [
[
[
966,
24,
5
]
],
[
[
966,
24,
1252
],
[
1252,
23,
5
]
],
[
[
966,
24,
245
],
[
245,
24,
5
]
],
[
[
966,
63,
176
],
[
176,
24,
... | [
[
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
... | Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Octreotide (Compound) resembles Pasireotide (Compound) and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Octreotide may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Liraglutide
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Liraglutide |
DB00957 | DB06206 | 873 | 1,268 | [
"DDInter1314",
"DDInter1719"
] | Norgestimate | Sugammadex | Norgestimate was first described in the literature in 1977. It was developed by Ortho Pharmaceutical Corporation as part of an effort to develop new hormonal contraceptives with reduced adverse effects. It is commonly formulated with [ethinylestradiol] as a combined oral contraceptive that can also be used to treat moderate acne vulgaris.[L11845,L11848] Norgestimate was granted FDA approval on 29 December 1989. | Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery. Rocuronium bromide and vecuronium bromide are neuromuscular blocking medications that cause temporary paralysis and are especially useful for general anesthesia, ventilation, or tracheal intubation that patients may require for surgery. Sugammadex provides a new treatment option to reverse the effects of those medications and possibly help patients recover sooner post-surgery. Sugammadex (brand name Bridion) is marketed by Merck Sharp and Dohme, and was approved by the United States FDA on December 15, 2015. | Major | 2 | [
[
[
873,
25,
1268
]
],
[
[
873,
40,
615
],
[
615,
64,
1268
]
],
[
[
873,
40,
1657
],
[
1657,
25,
1268
]
],
[
[
873,
40,
615
],
[
615,
... | [
[
[
"Norgestimate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sugammadex"
]
],
[
[
"Norgestimate",
"{u} (Compound) resembles {v} (Compound)",
"Norelgestromin"
],
[
"Norelgestromin",
"{u} may lead to a major li... | Norgestimate (Compound) resembles Norelgestromin (Compound) and Norelgestromin may lead to a major life threatening interaction when taken with Sugammadex
Norgestimate (Compound) resembles Desogestrel (Compound) and Desogestrel may lead to a major life threatening interaction when taken with Sugammadex
Norgestimate (Compound) resembles Norelgestromin (Compound) and Norelgestromin (Compound) resembles Desogestrel (Compound) and Desogestrel may lead to a major life threatening interaction when taken with Sugammadex
Norgestimate (Compound) resembles Desogestrel (Compound) and Desogestrel (Compound) resembles Norelgestromin (Compound) and Norelgestromin may lead to a major life threatening interaction when taken with Sugammadex
Norgestimate (Compound) resembles Etonogestrel (Compound) and Etonogestrel (Compound) resembles Norelgestromin (Compound) and Norelgestromin may lead to a major life threatening interaction when taken with Sugammadex
Norgestimate may lead to a major life threatening interaction when taken with Griseofulvin and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Anisindione and Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Sugammadex
Norgestimate (Compound) resembles Norelgestromin (Compound) and Norelgestromin (Compound) resembles Etonogestrel (Compound) and Etonogestrel may lead to a major life threatening interaction when taken with Sugammadex
Norgestimate may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Anisindione and Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Sugammadex
Norgestimate may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Anisindione and Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Sugammadex |
DB00209 | DB00577 | 352 | 1,295 | [
"DDInter1886",
"DDInter1908"
] | Trospium | Valaciclovir | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevus Pharmaceutical Inc._ and was granted FDA approval in 2007. | Valaciclovir (valacyclovir), also known as _Valtrex_, is an antiviral drug that has been used to manage and treat various herpes infections for more than 2 decades. It was initially approved by the FDA in 1995 [FDA label] and marketed by GlaxoSmithKline . Valacyclovir is the L-valine ester of aciclovir. It is a member of the purine (guanine) nucleoside analog drug class . This class of drugs forms an important part of hepatitis, HIV, and cytomegalovirus drug regimens . One major use of valacyclovir is the treatment of genital herpes episodes or outbreaks. Genital herpes is a frequently diagnosed sexually transmitted disease which currently affects more than 400 million individuals worldwide. It is caused by infection with the herpes simplex virus (HSV). Infection with this virus is lifelong with periodic episodes of reactivation . | Moderate | 1 | [
[
[
352,
24,
1295
]
],
[
[
352,
24,
563
],
[
563,
40,
1295
]
],
[
[
352,
21,
28868
],
[
28868,
60,
1295
]
],
[
[
352,
24,
752
],
[
752,
... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valaciclovir"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
],
[
... | Trospium may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir (Compound) resembles Valaciclovir (Compound)
Trospium (Compound) causes Stomatitis (Side Effect) and Stomatitis (Side Effect) is caused by Valaciclovir (Compound)
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Valaciclovir
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir (Compound) resembles Penciclovir (Compound) and Penciclovir (Compound) resembles Valaciclovir (Compound)
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir (Compound) resembles Ganciclovir (Compound) and Ganciclovir (Compound) resembles Valaciclovir (Compound)
Trospium (Compound) causes Stomatitis (Side Effect) and Stomatitis (Side Effect) is caused by Ganciclovir (Compound) and Ganciclovir (Compound) resembles Valaciclovir (Compound)
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Valaciclovir (Compound)
Trospium (Compound) causes Renal pain (Side Effect) and Renal pain (Side Effect) is caused by Pentamidine (Compound) and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Valaciclovir
Trospium (Compound) causes Rhinitis (Side Effect) and Rhinitis (Side Effect) is caused by Mycophenolic acid (Compound) and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Valaciclovir |
DB00176 | DB00835 | 529 | 100 | [
"DDInter770",
"DDInter245"
] | Fluvoxamine | Brompheniramine | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine. | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
529,
24,
100
]
],
[
[
529,
24,
832
],
[
832,
24,
100
]
],
[
[
529,
24,
649
],
[
649,
63,
100
]
],
[
[
529,
6,
8374
],
[
8374,
45... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
... | Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Fluvoxamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Brompheniramine (Compound)
Fluvoxamine (Compound) downregulates TUBB6 (Gene) and TUBB6 (Gene) is downregulated by Brompheniramine (Compound)
Fluvoxamine may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Fluvoxamine may lead to a major life threatening interaction when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Brompheniramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Brompheniramine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine |
DB05294 | DB09268 | 1,069 | 1,662 | [
"DDInter1917",
"DDInter1464"
] | Vandetanib | Picosulfuric acid | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years. | Major | 2 | [
[
[
1069,
25,
1662
]
],
[
[
1069,
63,
1252
],
[
1252,
23,
1662
]
],
[
[
1069,
64,
1164
],
[
1164,
24,
1662
]
],
[
[
1069,
25,
484
],
[
484... | [
[
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Vandetanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
"Digoxi... | Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid
Vandetanib may lead to a major life threatening interaction when taken with Trimipramine and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Vandetanib may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Vandetanib may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Vandetanib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Olanzapine and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Dalfampridine and Dalfampridine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Vandetanib may lead to a major life threatening interaction when taken with Sotalol and Sotalol may lead to a major life threatening interaction when taken with Picosulfuric acid
Vandetanib may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Picosulfuric acid |
DB00398 | DB00927 | 79 | 1,559 | [
"DDInter1702",
"DDInter712"
] | Sorafenib | Famotidine | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma. | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</sub> receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory disease, famotidine was about 20 to 50 times more potent at inhibiting gastric acid secretion than [cimetidine] and eight times more potent than [ranitidine] on a weight basis. Famotidine is used in various over-the-counter and off-label uses. While oral formulations of famotidine are more commonly used, the intravenous solution of the drug is available for use in hospital settings. | Moderate | 1 | [
[
[
79,
24,
1559
]
],
[
[
79,
6,
10215
],
[
10215,
45,
1559
]
],
[
[
79,
18,
1918
],
[
1918,
57,
1559
]
],
[
[
79,
21,
28826
],
[
28826,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
]
],
[
[
"Sorafenib",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",... | Sorafenib (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Famotidine (Compound)
Sorafenib (Compound) downregulates PCNA (Gene) and PCNA (Gene) is downregulated by Famotidine (Compound)
Sorafenib (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Famotidine (Compound)
Sorafenib may cause a minor interaction that can limit clinical effects when taken with Raltegravir and Raltegravir may cause a minor interaction that can limit clinical effects when taken with Famotidine
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Famotidine
Sorafenib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Famotidine
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Famotidine
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine and Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Famotidine
Sorafenib may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Famotidine |
DB00397 | DB09241 | 1,466 | 1,629 | [
"DDInter1458",
"DDInter1186"
] | Phenylpropanolamine | Methylene blue | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs entered the market. Its use as an urinary tract antiseptic has also been investigated. Methylthioninium chloride (INN, or methylene blue, proposed trade name Rember) is an investigational drug being developed by the University of Aberdeen and TauRx Therapeutics that has been shown in early clinical trials to be an inhibitor of Tau protein aggregation. The drug is of potential interest for the treatment of patients with Alzheimer's disease. | Major | 2 | [
[
[
1466,
25,
1629
]
],
[
[
1466,
24,
1052
],
[
1052,
24,
1629
]
],
[
[
1466,
63,
1000
],
[
1000,
24,
1629
]
],
[
[
1466,
35,
584
],
[
584... | [
[
[
"Phenylpropanolamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
],
... | Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Guanadrel and Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Phenylpropanolamine (Compound) resembles Levonordefrin (Compound) and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Levonordefrin and Levonordefrin may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol and Levosalbutamol may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Phenylpropanolamine may lead to a major life threatening interaction when taken with Phentermine and Phentermine may lead to a major life threatening interaction when taken with Methylene blue
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Methylphenidate and Methylphenidate may lead to a major life threatening interaction when taken with Methylene blue
Phenylpropanolamine (Compound) resembles Phenelzine (Compound) and Phenylpropanolamine may lead to a major life threatening interaction when taken with Phenelzine and Phenelzine may lead to a major life threatening interaction when taken with Methylene blue
Phenylpropanolamine (Compound) resembles Dextroamphetamine (Compound) and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Dextroamphetamine and Dextroamphetamine may lead to a major life threatening interaction when taken with Methylene blue
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine and Phenylephrine may lead to a major life threatening interaction when taken with Methylene blue |
DB00675 | DB08865 | 888 | 1,593 | [
"DDInter1744",
"DDInter448"
] | Tamoxifen | Crizotinib | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. Tamoxifen was granted FDA approval on 30 December 1977. | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements. | Major | 2 | [
[
[
888,
25,
1593
]
],
[
[
888,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
888,
7,
7260
],
[
7260,
46,
1593
]
],
[
[
888,
18,
13230
],
[
13230,
... | [
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Tamoxifen",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Crizotini... | Tamoxifen (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Tamoxifen (Compound) upregulates MVD (Gene) and MVD (Gene) is upregulated by Crizotinib (Compound)
Tamoxifen (Compound) downregulates TIPARP (Gene) and TIPARP (Gene) is upregulated by Crizotinib (Compound)
Tamoxifen (Compound) downregulates HSPD1 (Gene) and HSPD1 (Gene) is downregulated by Crizotinib (Compound)
Tamoxifen (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Crizotinib (Compound)
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Tamoxifen may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Tamoxifen may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Crizotinib |
DB00046 | DB00938 | 1,179 | 455 | [
"DDInter940",
"DDInter1635"
] | Insulin lispro | Salmeterol | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. Salmeterol was granted FDA approval on 4 February 1994. | Moderate | 1 | [
[
[
1179,
24,
455
]
],
[
[
1179,
24,
1523
],
[
1523,
25,
455
]
],
[
[
1179,
24,
688
],
[
688,
63,
455
]
],
[
[
1179,
24,
167
],
[
167,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
],
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol may lead to a major life threatening interaction when taken with Salmeterol
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Salmeterol
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a minor interaction that can limit clinical effects when taken with Salmeterol
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Bisoprolol and Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Insulin lispro may lead to a major life threatening interaction when taken with Norfloxacin and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Insulin lispro may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir and Fosamprenavir may lead to a major life threatening interaction when taken with Salmeterol |
DB00328 | DB11817 | 831 | 1,259 | [
"DDInter921",
"DDInter165"
] | Indomethacin | Baricitinib | Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlorobenzoyl)25-methoxy-2-methylindole-3-acetic acid. The pharmacological effect of indometacin is not fully understood, however, it is thought to be mediated through potent and nonselective inhibition of the enzyme cyclooxygenase (COX), which is the main enzyme responsible for catalyzes the rate-limiting step in prostaglandin and thromboxane biosynthesis via the arachidonic acid (AA) pathway. Indometacin was first discovered in 1963 and it was first approved for use in the U.S. by | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults and was later approved by the FDA in 2018. The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe. While baricitinib was granted emergency use as a treatment for COVID-19 in combination with [remdesivir] under the Emergency Use Authorization (EUA) in November 2020, the FDA fully approved the use of baricitinib for the treatment of COVID-19 in May 2022. | Moderate | 1 | [
[
[
831,
24,
1259
]
],
[
[
831,
24,
1274
],
[
1274,
24,
1259
]
],
[
[
831,
40,
24
],
[
24,
24,
1259
]
],
[
[
831,
24,
384
],
[
384,
... | [
[
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baricitinib"
]
],
[
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
... | Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Indomethacin (Compound) resembles Tolmetin (Compound) and Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Baricitinib
Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may lead to a major life threatening interaction when taken with Baricitinib
Indomethacin may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may lead to a major life threatening interaction when taken with Baricitinib
Indomethacin may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan and Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Baricitinib
Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Baricitinib
Indomethacin may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide may lead to a major life threatening interaction when taken with Baricitinib
Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Nabumetone and Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib |
DB00374 | DB01018 | 1,061 | 1,364 | [
"DDInter1852",
"DDInter847"
] | Treprostinil | Guanfacine | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease.[L41855,L41860] The first agent approved for the treatment of PAH was [epoprostenol], a synthetic prostacyclin that significantly increases patients' quality of life. However, the use of epoprostenol is limited due to its short half-life (3-5 min) and instability at room temperature.[A248770,A248775] The use of more stable alternatives such as treprostinil provides patients with PAH with more treatment options. Treprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension. It is available in the following routes of administration: subcut | Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approval on 27 October 1986. | Moderate | 1 | [
[
[
1061,
24,
1364
]
],
[
[
1061,
24,
1512
],
[
1512,
1,
1364
]
],
[
[
1061,
6,
6017
],
[
6017,
45,
1364
]
],
[
[
1061,
21,
28757
],
[
287... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanfacine"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
... | Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac (Compound) resembles Guanfacine (Compound)
Treprostinil (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Guanfacine (Compound)
Treprostinil (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Guanfacine (Compound)
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Guanfacine
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil and Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Guanfacine
Treprostinil may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Guanfacine
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine and Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Guanfacine
Treprostinil (Compound) resembles Epoprostenol (Compound) and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Guanfacine
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Guanfacine |
DB00280 | DB00741 | 494 | 167 | [
"DDInter575",
"DDInter885"
] | Disopyramide | Hydrocortisone | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952. | Moderate | 1 | [
[
[
494,
24,
167
]
],
[
[
494,
24,
1220
],
[
1220,
40,
167
]
],
[
[
494,
24,
870
],
[
870,
1,
167
]
],
[
[
494,
6,
8374
],
[
8374,
4... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
... | Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound)
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Hydrocortisone (Compound)
Disopyramide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Hydrocortisone (Compound)
Disopyramide (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Hydrocortisone (Compound)
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Hydrocortisone
Disopyramide may lead to a major life threatening interaction when taken with Orciprenaline and Orciprenaline may cause a minor interaction that can limit clinical effects when taken with Hydrocortisone
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone
Disopyramide may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone |
DB04575 | DB06404 | 35 | 1,514 | [
"DDInter1555",
"DDInter869"
] | Quinestrol | Human C1-esterase inhibitor | The 3-cyclopentyl ether of ethinyl estradiol. | C1 Esterase Inhibitor (Human) is composed of purified endogenous complement component-1 esterase inhibitor (hC1INH) isolated from human plasma. The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways.[L16586, L16606] This drug is indicated for prophylaxis and treatment of Hereditary Angioedema (HAE), a human genetic disorder caused by a shortage of C1 inhibitor activity that results in an overreaction of the immune system. The disease is characterized by acute attacks of painful, and in some cases, fatal swelling of several soft tissues or edema, which may last up to five days when untreated.[L16586, L16606] | Moderate | 1 | [
[
[
35,
24,
1514
]
],
[
[
35,
40,
1438
],
[
1438,
24,
1514
]
],
[
[
35,
1,
984
],
[
984,
24,
1514
]
],
[
[
35,
25,
350
],
[
350,
64,... | [
[
[
"Quinestrol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human C1-esterase inhibitor"
]
],
[
[
"Quinestrol",
"{u} (Compound) resembles {v} (Compound)",
"Estradiol"
],
[
"Estradiol",
"{u} may ... | Quinestrol (Compound) resembles Estradiol (Compound) and Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Human C1-esterase inhibitor
Quinestrol (Compound) resembles Danazol (Compound) and Danazol may cause a moderate interaction that could exacerbate diseases when taken with Human C1-esterase inhibitor
Quinestrol may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may lead to a major life threatening interaction when taken with Human C1-esterase inhibitor
Quinestrol may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Human C1-esterase inhibitor
Quinestrol (Compound) resembles Estradiol (Compound) and Estradiol (Compound) resembles Estrone (Compound) and Estrone may cause a moderate interaction that could exacerbate diseases when taken with Human C1-esterase inhibitor
Quinestrol (Compound) resembles Danazol (Compound) and Danazol (Compound) resembles Testolactone (Compound) and Testolactone may cause a moderate interaction that could exacerbate diseases when taken with Human C1-esterase inhibitor
Quinestrol (Compound) resembles Conjugated estrogens (Compound) and Conjugated estrogens (Compound) resembles Estradiol (Compound) and Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Human C1-esterase inhibitor
Quinestrol may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may lead to a major life threatening interaction when taken with Testolactone and Testolactone may cause a moderate interaction that could exacerbate diseases when taken with Human C1-esterase inhibitor
Quinestrol may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Ospemifene and Ospemifene may cause a moderate interaction that could exacerbate diseases when taken with Human C1-esterase inhibitor |
DB00008 | DB00704 | 491 | 267 | [
"DDInter1407",
"DDInter1263"
] | Peginterferon alfa-2a | Naltrexone | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) resulting in less use of Peginterferon alfa-2a. Peginterferon alfa-2a is derived from the alfa-2a moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Moderate | 1 | [
[
[
491,
24,
267
]
],
[
[
491,
24,
522
],
[
522,
24,
267
]
],
[
[
491,
24,
850
],
[
850,
63,
267
]
],
[
[
491,
25,
72
],
[
72,
63,
... | [
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafir... | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Peginterferon alfa-2a may lead to a major life threatening interaction when taken with Eltrombopag and Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Peginterferon alfa-2a may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Peginterferon alfa-2a may cause a minor interaction that can limit clinical effects when taken with Methadone and Methadone may lead to a major life threatening interaction when taken with Naltrexone
Peginterferon alfa-2a may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Naltrexone
Peginterferon alfa-2a may lead to a major life threatening interaction when taken with Tramadol and Tramadol may lead to a major life threatening interaction when taken with Naltrexone
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone may lead to a major life threatening interaction when taken with Naltrexone
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Chlorzoxazone and Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone |
DB00060 | DB00795 | 912 | 50 | [
"DDInter947",
"DDInter1725"
] | Interferon beta-1a | Sulfasalazine | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down into [mesalazine] and [sulfapyridine], 2 compounds that carry out the main pharmacological activity of sulfasalazine. Sulfasalazine was first used in 1940 for rheumatic polyarthritis, and has been firmly established itself as one fo the most useful disease-modifying antirheumatic drug (DMARD). Compared to the first line treatment of RA like methotrexate, sulfasalazine is almost as efficacious as methotrexate although with slightly less tolerability. However, sulfasalazine has less teratogenic side effects and faster onset of action compared to conventional DMARD. Sulfasalazine fell out of favor as the drug of choice for RA due to poorly designed clinical trials in 1950 but regained interest from the clinical community in the late 1970. Although sulfasalazine is only approved by the FDA for ulcerative colitis, research have shown that sulfasalazine is also beneficial for patients with Crohn's disease. Meta-analysis of 19 randomized controlled trials indicated that sulfasalazine is superior to placebo in inducing remission; however, with no supported evidence of mucosal healing, sulfasalazine is not FDA-recommmended for treatment of Crohn's disease.[A255597,A255602,A255607] | Moderate | 1 | [
[
[
912,
24,
50
]
],
[
[
912,
24,
161
],
[
161,
1,
50
]
],
[
[
912,
63,
305
],
[
305,
24,
50
]
],
[
[
912,
24,
546
],
[
546,
63,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfadia... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Sulfadiazine and Sulfadiazine (Compound) resembles Sulfasalazine (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate and Lutetium Lu 177 dotatate may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine
Interferon beta-1a may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may lead to a major life threatening interaction when taken with Sulfasalazine
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Anisindione and Anisindione may lead to a major life threatening interaction when taken with Sulfasalazine
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Sulfasalazine
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Sulfadiazine and Sulfadiazine (Compound) resembles Sulfaphenazole (Compound) and Sulfaphenazole (Compound) resembles Sulfasalazine (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Sulfadiazine and Sulfadiazine (Compound) resembles Sulfasalazine (Compound) |
DB01069 | DB09420 | 401 | 1,074 | [
"DDInter1533",
"DDInter953"
] | Promethazine | Iodide I-123 | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000] | Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect the decay by electron capture to tellurium-123. Iodine is commonly used in thyroid function diagnostic tests as this gland normally absorbs iodine through the diet for formation of the thyroid hormones triiodothyronine (T3) and its prohormone, thyroxine (T4). Radioactive I-123 in particular is effective for this use as its half-life of approximately 13.13 h (hours) is ideal for the 24-h (hour) iodine uptake test and it has a reduced radiation burden as compared to I-131. | Moderate | 1 | [
[
[
401,
24,
1074
]
],
[
[
401,
24,
516
],
[
516,
24,
1074
]
],
[
[
401,
63,
902
],
[
902,
24,
1074
]
],
[
[
401,
62,
1247
],
[
1247,
... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]... | Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Promethazine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Promethazine may lead to a major life threatening interaction when taken with Iohexol and Iohexol may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Promethazine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole (Compound) resembles Sulfadiazine (Compound) and Sulfadiazine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 |
DB00692 | DB01037 | 274 | 1,161 | [
"DDInter1448",
"DDInter1653"
] | Phentolamine | Selegiline | Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[A261781, A261786] It has several therapeutic uses, including the treatment of hypertensive episodes, prevention of norepinephrine-induced extravasation, diagnosis of pheochromocytoma, reversal of soft-tissue anesthesia, and treatment of pharmacologically-induced mydriasis.[L48420, L48415, L48390] Phentolamine is administered intravenously, intramuscularly, submucosally, and topically. | A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl. | Moderate | 1 | [
[
[
274,
24,
1161
]
],
[
[
274,
24,
551
],
[
551,
1,
1161
]
],
[
[
274,
21,
28722
],
[
28722,
60,
1161
]
],
[
[
274,
62,
176
],
[
176,
... | [
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selegiline"
]
],
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
],
... | Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine (Compound) resembles Selegiline (Compound)
Phentolamine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Selegiline (Compound)
Phentolamine may cause a minor interaction that can limit clinical effects when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Selegiline
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Selegiline
Phentolamine may cause a minor interaction that can limit clinical effects when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Selegiline
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Selegiline
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Selegiline
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Selegiline
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine (Compound) resembles Metamfetamine (Compound) and Metamfetamine (Compound) resembles Selegiline (Compound) |
DB00734 | DB06691 | 1,664 | 849 | [
"DDInter1605",
"DDInter1155"
] | Risperidone | Mepyramine | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone). Schizophrenia and various mood disorders are thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively. Risperidone is thought to reduce this overactivity through inhibition of dopaminergic D2 receptors and serotonergic 5-HT2A receptors in the brain. Risperidone binds with a very high affinity to 5-HT2A receptors, approximately 10-20 fold greater than the drug's | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions. | Moderate | 1 | [
[
[
1664,
24,
849
]
],
[
[
1664,
63,
1594
],
[
1594,
24,
849
]
],
[
[
1664,
24,
272
],
[
272,
24,
849
]
],
[
[
1664,
6,
12523
],
[
12523,
... | [
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Risperidone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mepyramine (Compound)
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium and Umeclidinium may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Risperidone may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Risperidone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Risperidone (Compound) resembles Iloperidone (Compound) and Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Mepyramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) resembles Chloropyramine (Compound) and Chloropyramine (Compound) resembles Mepyramine (Compound) |
DB00348 | DB00675 | 254 | 888 | [
"DDInter1300",
"DDInter1744"
] | Nitisinone | Tamoxifen | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. Tamoxifen was granted FDA approval on 30 December 1977. | Moderate | 1 | [
[
[
254,
24,
888
]
],
[
[
254,
21,
29152
],
[
29152,
60,
888
]
],
[
[
254,
24,
469
],
[
469,
62,
888
]
],
[
[
254,
63,
1648
],
[
1648,
... | [
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
]
],
[
[
"Nitisinone",
"{u} (Compound) causes {v} (Side Effect)",
"Thirst"
],
[
"Thirst",
"{u} (Side Effect) is caused by {... | Nitisinone (Compound) causes Thirst (Side Effect) and Thirst (Side Effect) is caused by Tamoxifen (Compound)
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Bromocriptine and Bromocriptine may cause a minor interaction that can limit clinical effects when taken with Tamoxifen
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Nafcillin and Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen
Nitisinone may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Tamoxifen
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may lead to a major life threatening interaction when taken with Tamoxifen
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone (Compound) resembles Tamoxifen (Compound) and Methadone may lead to a major life threatening interaction when taken with Tamoxifen |
DB00384 | DB13620 | 1,275 | 948 | [
"DDInter1859",
"DDInter1499"
] | Triamterene | Potassium gluconate | Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension. It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. Since it acts on the distal nephron where only a small fraction of sodium ion reabsorption occurs, triamterene is reported to have limited diuretic efficacy. Due to its effects on increased serum potassium levels, triamterene is associated with a risk of producing hyperkalemia. Triamterene is a weak antagonist of folic acid, and a photosensitizing drug. Triamterene was approved by the Food and Drug Administration in the U.S. in 1964. Currently, triamterene is used in the treatment of edema associated with various | Potassium gluconate is a salt of and is classified as a food additive by the FDA . It is also used as a potassium supplement . Potassium is an essential nutrient. It is the most abundant cation in the intracellular fluid, where it plays a key role in maintaining cell function . In dietary supplements, potassium is often present as potassium chloride, but many other forms—including potassium citrate, phosphate, aspartate, bicarbonate, and **gluconate**—are also used . Potassium gluconate is believed to be more palatable and non-acidifying than potassium chloride (KCl) . | Major | 2 | [
[
[
1275,
25,
948
]
],
[
[
1275,
24,
848
],
[
848,
24,
948
]
],
[
[
1275,
24,
848
],
[
848,
63,
1027
],
[
1027,
24,
948
]
],
[
[
1275,
... | [
[
[
"Triamterene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium gluconate"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"... | Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Potassium gluconate
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam and Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Potassium gluconate
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Potassium gluconate
Triamterene may lead to a major life threatening interaction when taken with Potassium perchlorate and Potassium perchlorate may cause a minor interaction that can limit clinical effects when taken with Insulin glargine and Insulin glargine may cause a minor interaction that can limit clinical effects when taken with Potassium gluconate
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen (Compound) resembles Ibuprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Potassium gluconate
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a minor interaction that can limit clinical effects when taken with Potassium gluconate
Triamterene may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may cause a minor interaction that can limit clinical effects when taken with Insulin glulisine and Insulin glulisine may cause a minor interaction that can limit clinical effects when taken with Potassium gluconate
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a minor interaction that can limit clinical effects when taken with Potassium gluconate
Triamterene may lead to a major life threatening interaction when taken with Potassium perchlorate and Potassium perchlorate may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Potassium gluconate |
DB00364 | DB00448 | 417 | 1,215 | [
"DDInter1717",
"DDInter1022"
] | Sucralfate | Lansoprazole | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protecting cells in the gastrointestinal tract from damage caused by agents such as gastric acid, bile salts, alcohol, and acetylsalicylic acid (aspirin), among other substances [A177655, F4519]. Sucralfate has been shown to be a well-tolerated and safe drug. It is sold under many brands and is available in both tablet and suspension forms. It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form [L6073, L6076]. | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other pathologies caused by excessive acid secretion. | Moderate | 1 | [
[
[
417,
24,
1215
]
],
[
[
417,
21,
28882
],
[
28882,
60,
1215
]
],
[
[
417,
62,
1031
],
[
1031,
23,
1215
]
],
[
[
417,
63,
1324
],
[
1324... | [
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
]
],
[
[
"Sucralfate",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increase... | Sucralfate (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Lansoprazole (Compound)
Sucralfate may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Lansoprazole
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Anisindione and Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole
Sucralfate may cause a minor interaction that can limit clinical effects when taken with Liotrix and Liotrix may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole
Sucralfate may cause a minor interaction that can limit clinical effects when taken with Liothyronine and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole
Sucralfate (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Rabeprazole (Compound) and Rabeprazole (Compound) resembles Lansoprazole (Compound)
Sucralfate may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole and Rabeprazole (Compound) resembles Lansoprazole (Compound) |
DB00421 | DB01240 | 443 | 885 | [
"DDInter1707",
"DDInter657"
] | Spironolactone | Epoprostenol | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered.[A11837, A178246] It is indicated to treat several conditions, including heart failure, edema, hyperaldosteronism, and hypertension. Off-label uses of spironolactone include hirsutism, female pattern hair loss, and adult acne vulgaris.[A178135, A261025] Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.[A178243, L6187] | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
443,
24,
885
]
],
[
[
443,
63,
1061
],
[
1061,
1,
885
]
],
[
[
443,
21,
28921
],
[
28921,
60,
885
]
],
[
[
443,
24,
1512
],
[
1512,
... | [
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
... | Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Spironolactone (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Epoprostenol (Compound)
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Spironolactone may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Spironolactone (Compound) resembles Eplerenone (Compound) and Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin and Tinzaparin may lead to a major life threatening interaction when taken with Epoprostenol
Spironolactone may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may lead to a major life threatening interaction when taken with Epoprostenol |
DB01157 | DB08826 | 304 | 1,292 | [
"DDInter1875",
"DDInter489"
] | Trimetrexate | Deferiprone | A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect. | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA approved on October 14, 2011. | Major | 2 | [
[
[
304,
25,
1292
]
],
[
[
304,
21,
28722
],
[
28722,
60,
1292
]
],
[
[
304,
63,
482
],
[
482,
25,
1292
]
],
[
[
304,
24,
4
],
[
4,
... | [
[
[
"Trimetrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Trimetrexate",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compo... | Trimetrexate (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Deferiprone (Compound)
Trimetrexate may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may lead to a major life threatening interaction when taken with Deferiprone
Trimetrexate may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Deferiprone
Trimetrexate may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Deferiprone
Trimetrexate may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Deferiprone
Trimetrexate may lead to a major life threatening interaction when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Deferiprone
Trimetrexate may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Deferiprone
Trimetrexate (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Didanosine (Compound) and Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Deferiprone
Trimetrexate (Compound) causes Blood bilirubin increased (Side Effect) and Blood bilirubin increased (Side Effect) is caused by Imatinib (Compound) and Imatinib may lead to a major life threatening interaction when taken with Deferiprone |
DB00580 | DB01097 | 311 | 1,377 | [
"DDInter1910",
"DDInter1033"
] | Valdecoxib | Leflunomide | Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke. | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
311,
25,
1377
]
],
[
[
311,
24,
126
],
[
126,
24,
1377
]
],
[
[
311,
24,
1411
],
[
1411,
63,
1377
]
],
[
[
311,
63,
245
],
[
245,
... | [
[
[
"Valdecoxib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
... | Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may lead to a major life threatening interaction when taken with Leflunomide
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Leflunomide
Valdecoxib may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Leflunomide
Valdecoxib may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Leflunomide
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may lead to a major life threatening interaction when taken with Leflunomide
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Leflunomide (Compound) |
DB01210 | DB09132 | 668 | 492 | [
"DDInter1050",
"DDInter797"
] | Levobunolol (ophthalmic) | Gadoteric acid | Levobunolol is a cyclic ketone that is 3,4-dihydronaphthalen-1-one substituted at position 5 by a 3-(tert-butylamino)-2-hydroxypropoxy group (the S-enantiomer). A non-selective beta-adrenergic antagonist used (as its hydrochloride salt) for treatment of glaucoma. It has a role as an antiglaucoma drug and a beta-adrenergic antagonist. It is a propanolamine, a cyclic ketone and an aromatic ether. It is a conjugate acid of a levobunolol(1+). It derives from a hydride of a tetralin. | Gadoteric acid, commonly used in the salt form gadoterate meglumine, is a macrocyclic, ionic gadolinium-based contrast agent (GBCA). It is composed of the organic acid DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) used for its chelating properties, and gadolinium (Gd3+). Gadoterate meglumine has one of the highest thermodynamic stability, apparent stability, and kinetic stability, partly due to its macrocyclic structure, and thus has a more favorable safety profile due to a decreased tendency of gadolinium dechelation.[A263141,A263106] Gadoterate is approved by the FDA under the brand name DOTAREM on 20th March 2013 for intravenous uses with magnetic resonance imaging (MRI) in the brain (intracranial), spine, and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood-brain barrier (BBB) and/or abnormal vascularity. | Moderate | 1 | [
[
[
668,
24,
492
]
],
[
[
668,
1,
699
],
[
699,
24,
492
]
],
[
[
668,
40,
461
],
[
461,
24,
492
]
],
[
[
668,
1,
699
],
[
699,
40,
... | [
[
[
"Levobunolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadoteric acid"
]
],
[
[
"Levobunolol",
"{u} (Compound) resembles {v} (Compound)",
"Nadolol"
],
[
"Nadolol",
"{u} may cause a moderat... | Levobunolol may cause a moderate interaction that could exacerbate diseases when taken with Gadoteric acid
Levobunolol (Compound) resembles Nadolol (Compound) and Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Gadoteric acid
Levobunolol (Compound) resembles Timolol (Compound) and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Gadoteric acid
Levobunolol (Compound) resembles Nadolol (Compound) and Nadolol (Compound) resembles Pindolol (Compound) and Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Gadoteric acid
Levobunolol (Compound) downregulates CAST (Gene) and CAST (Gene) is downregulated by Nicardipine (Compound) and Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Gadoteric acid
Levobunolol (Compound) resembles Pindolol (Compound) and Pindolol (Compound) resembles Nadolol (Compound) and Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Gadoteric acid
Levobunolol (Compound) causes Syncope (Side Effect) and Syncope (Side Effect) is caused by Nicardipine (Compound) and Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Gadoteric acid
Levobunolol (Compound) resembles Pindolol (Compound) and Pindolol (Compound) resembles Bisoprolol (Compound) and Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Gadoteric acid
Levobunolol may cause a moderate interaction that could exacerbate diseases when taken with Gadoxetic acid and Gadoxetic acid may cause a moderate interaction that could exacerbate diseases when taken with Nicardipine and Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Gadoteric acid
Levobunolol may cause a moderate interaction that could exacerbate diseases when taken with Gadoxetic acid and Gadoxetic acid may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine and Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Gadoteric acid |
DB01018 | DB11827 | 1,364 | 433 | [
"DDInter847",
"DDInter669"
] | Guanfacine | Ertugliflozin | Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approval on 27 October 1986. | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
1364,
24,
433
]
],
[
[
1364,
40,
390
],
[
390,
24,
433
]
],
[
[
1364,
63,
251
],
[
251,
24,
433
]
],
[
[
1364,
24,
820
],
[
820,
... | [
[
[
"Guanfacine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Guanfacine",
"{u} (Compound) resembles {v} (Compound)",
"Guanabenz"
],
[
"Guanabenz",
"{u} may cause a modera... | Guanfacine (Compound) resembles Guanabenz (Compound) and Guanabenz may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Guanfacine may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Guanfacine (Compound) resembles Guanabenz (Compound) and Guanabenz may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Ertugliflozin
Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Ertugliflozin
Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.